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9Introduction 
Heart failure - general aspects 
Definition 
Heart failure (HF) has been defined as a clinical syndrome in which patients have 
symptoms such as breathlessness at rest or with exercise, and/or fatigue, signs of 
fluid retention (such as pulmonary congestion or ankle swelling) in addition to
objective evidence of an abnormality of the structure or function of the heart at rest1.
Epidemiology 
HF is the leading cause of death in developed countries and is the leading cause of 
hospitalization in elderly patients. The prevalence of HF is according to the European 
Society of Cardiology between 2 and 3% and rises sharply at ~75 years of age, with
prevalence in 70- to 80-year-old people at approximately 10 to 20%1. Overall 
prevalence of HF is increasing due to aging of the population. In the 1997 Rotterdam 
study, the life time risk of HF for a person at 55 years of age was estimated at 33.0% 
in men and 28.5% in women2. The age-adjusted mortality from HF is falling at least 
in part due to modern treatment in some countries3-6. Unfortunately, despite 
contemporary medical management, long-time survival rates are poor, and overall 
50% of patients are dead 4 years after diagnosis1.
Aetiology 
Coronary heart disease is by far the most common cause of HF, and is the initiating 
cause in ~70% of the HF patients5,7. Cardiac valve disease accounts for 10%, and 
cardiomyopathies (hypertrophic, dilated, restrictive, arrhythmogenic right ventricular 
and unclassified cardiomyopathies) for another 10%1.
Heart failure in children 
The most common cause of paediatric HF is congenital cardiac malformations8, but
cardiomyopathies are the most common cause in children with a structurally normal 
heart. The remarkable improvement in survival of patients with congenital heart 
disease has led to a continually growing number of grown-up congenital heart 
disease (GUCH) patients, in particular those with a more complex disease9. HF is a 
frequent problem in the GUCH population. A major difference between adult and 
paediatric heart disease is that in paediatrics, much of the pathology is due to an 
abnormal right ventricle (RV), either due to congenital cardiac malformations or 
pulmonary hypertension. In congenital cardiac malformations, RV function can be 
affected in several ways. For example, in hypoplastic right heart syndromes, the three 
parts of the RV do not form normally or may be missing entirely. There may be 
defects in the interventricular septum, or abnormal left ventricle (LV) function, 
which in turn affect RV contraction. Volume overload of the RV can arise through 
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significant pulmonary or tricuspid valve insufficiency. The RV can experience 
increased afterload if there is right ventricular outflow obstruction at the 
subpulmonary, pulmonary, or suprapulmonary level, or if it is serving as the systemic 
ventricle. Depending on the severity of the different causes of RV affliction, cardiac 
remodelling and HF may occur. 
Cardiac remodelling 
Definition 
Cardiac remodelling is defined as genome expression, molecular, cellular, and 
interstitial changes that manifest clinically as changes in the size, shape, and function 
of the heart after cardiac injury10.
Remodelling of cardiomyocytes 
Cardiomyocytes have been the focus of considerable attention in studies of HF and 
remodelling, given their primary role in heart chamber contraction and their large 
contribution to the mass of the heart. The key events associated with cellular 
remodelling of cardiomyocytes are alterations in the contractile apparatus, cell size 
(hypertrophy), cell shape, and cell survival.
Extracellular matrix remodelling 
The extracellular matrix (ECM) in most tissues is composed of a complex 
arrangement of fibrillar collagen, elastin, proteoglycans, and adhesive proteins such 
as laminin and fibronectin. A paradigm shift in the understanding of matrix biology 
is taking place due to the evolving appreciation that the ECM not only provides the 
structural support for cells but also provides a dynamic microenvironment for cell 
signalling within the extracellular space11. The large number of fibroblasts in the 
heart serve the primary purpose of synthesizing and regulating the composition of the 
ECM12. Myocardial ECM are largely composed of a complex network of fibrillar 
collagen13. The content and function of myocardial proteoglycans are not well 
understood, but will be discussed in more detail below. 
Collagen network 
The most abundant collagen types in the heart (accounting for over 90%) are the type 
I and type III fibrillar collagens14. Type I collagen molecules assemble into thick 
fibres, which convey tensile strength and provide structural support. Type III 
collagens form a fine network of fibrils. A number of cardiovascular disorders 
including myocardial infarction (MI), hypertension, and HF are associated with 
alterations in the levels, type, stability, and organization of fibrillar collagen15.
Collagen accumulation is a classical response to tissue injury as seen in pressure-
overload16.
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Collagen cross-links 
In every tissue and organ of the human body, including the heart, collagen fibrils are 
stabilized by a process of maturation that involves the formation of biochemical 
cross-links17. In general, newly synthesized collagen is deficient in cross-links and 
relatively compliant, affording limited tensile strength. Through posttranslational 
processing, biochemical cross-links are eventually established in these fibres,
resulting in mature collagen that is dense, thick, and of considerable tensile strength. 
Reduction in collagen cross-links has been demonstrated in human and experimental 
dilated cardiomyopathy with LV dilatation18-20. Accordingly, the degree of collagen
cross-linking may have a greater impact on myocardial remodelling and function 
than collagen abundance or the ratio of collagen isoforms, but how, when, and why 
details of collagen cross-linking are not well understood.
Collagen architecture 
The three-dimensional architecture of the fibrillar collagen network is complex and 
appears to be highly regulated. Studies indicate that the normal collagen weave is 
considerably disrupted and degraded in the failing myocardium, and the fibres
become less frequent and reduced in thickness21. The orientation and spatial 
organization of cells within the ECM may critically influence cellular responses to 
regulatory signals, such as those induced during cardiac remodelling and failure. 
MMPs and matrix remodelling: key concepts 
Matrix metalloproteinases (MMPs) are members of an enzyme family that can 
catalyse the normal turnover of ECM macromolecules such as collagens and 
proteoglycans (i.e. decorin, biglycan, fibromodulin and lumican). In the myocardium, 
both fibroblasts and mast cells are believed to synthesize and secrete the majority of 
the MMPs into the extracellular space22,23. MMP expression and activity are elevated 
in failing hearts of diverse aetiology, suggesting that matrix remodelling by MMPs is 
a common response of the myocardium to tissue injury22-25. For example, MMP-9
may be particularly relevant to the HF process, as it is consistently expressed and 
activated in human failing myocardium22-27. In summary, MMPs disrupt the 
composition and organization of the ECM in the failing heart, and in so doing, 
trigger progressive LV dilatation, thinning of the ventricular walls, and cardiac 
dysfunction.
Regulation of MMP activity 
A number of processes regulate the balance of MMP activity including MMP
expression and secretion into the ECM, activation of latent MMPs to bioactive 
forms, and competitive inhibition of activated MMPs by endogenous inhibitors28. At 
the level of MMP gene expression and secretion into the ECM, cytokines and other 
growth factors that are known to be increased in the failing heart have also been 
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identified as important physiological MMP gene inducers25. The effects of 
proinflammatory cytokines on ECM homeostasis via MMP expression and activity 
represent a possible mechanism for the cytokine hypothesis of remodelling and 
failure. Beyond their effects on matrix metabolism, MMPs are capable of modulating 
inflammatory pathways by processing cytokines, chemokines and growth factors29.
MMP-mediated proteolysis may inactivate a chemokine, generate antagonistic 
derivatives capable of binding to a chemokine receptor without inducing a 
chemotactic response, or may result in formation of a truncated chemokine with 
more potent activity30. In addition, MMPs may interfere with chemokine binding to 
glycosaminoglycans, a molecular step that is critical for chemotactic effects31.
TIMPs: overview and key concepts 
An exciting development in the study of MMP biology was the discovery of a family 
of four inhibitors of MMPs known as the tissue inhibitor metalloproteinases
(TIMPs). These metalloproteinases bind to activated MMPs and form 1:1 enzyme–
inhibitor complexes that completely prevent the ability of MMPs to degrade 
substrates. A disruption in the balance of TIMPs relative to MMPs has been 
documented in association with the pathological turnover of ECM components in 
cardiovascular disease32.
Proteoglycans 
The basic proteoglycan unit consists of a core protein with one or more covalently
attached glycosaminoglycan (GAG) chain(s). Proteoglycans are a major component 
of the ECM, the filler substance existing between cells in an organism. In the ECM, 
proteoglycans form large complexes, both to other proteoglycans, hyaluronan and 
fibrous matrix proteins (such as collagen). Proteoglycans are also involved in binding 
cations (i.e. sodium, potassium and calcium) and water, and also in the regulation of
movement of molecules through the matrix. They can also affect the activity and 
stability of proteins and signaling molecules within the matrix. Individual functions 
of proteoglycans can be attributed to either the protein core or the attached GAG 
chains. Proteoglycans are classified into three major categories: (1) small leucine-
rich proteoglycans (SLRPs), (2) modular proteoglycans, and (3) cell-surface 
proteoglycans33.
Small leucine-rich proteoglycans 
SLRPs are so named for their small size (up to 42kD) and leucine-rich repeats 
(LRRs) of the core protein33. Recently, five distinct classes of SLRPs have been 
proposed based on shared biological activity and functions34. SLRP biology and 
function are complicated by their post-translational modifications including 
substitutions with glycosaminoglycan side chains of various types, namely 
chondroitin sulfate (CS), dermatan sulfate (DS), or keratan sulfate (KS). Over the last 
two decades, SLRPs have come to be recognized as regulators of collagen fibril 
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assembly, the strongest evidence being the disorganized collagen fibrils reported in 
decorin, fibromodulin and lumican null-mice that consequently lose connective 
tissue function35,36. SLRPs are now also recognized as key players in cell signaling, 
capable of influencing a host of cellular functions such as proliferations, survival, 
adhesion, migration and inflammatory responses37. Further, SLRPs have been shown 
to modify inflammatory responses through a number of different mechanisms such as 
activation of the Toll-like receptor (TLR) signaling pathways, binding and 
sequestering of cytokines and chemokines and interaction with MMPs38.
Inflammation and heart failure 
Cytokine hypothesis 
Inflammation is the classical biological response to injury and serves as a principal 
mechanism for organismal adaptation and tissue repair. In 1990, Levine et al. 
reported that TNF- is systemically elevated in patients with HF39. Since that time,
an overwhelming number of studies have described a primary role for activated 
proinflammatory cytokines in the disruption of cardiac structure and function 
associated with the progression of HF40. The results of these investigations have 
prompted the “cytokine hypothesis”41, raising the possibility that cytokines and other 
inflammatory mediators may be important targets for HF therapeutics. Despite 
compelling evidence in animal models, anti-TNF- approaches in patients with HF
have been uniformly unsuccessful42. Two large-scale multicentre clinical trials were 
prematurely halted due to the lack of a demonstrated benefit of anti-TNF- therapies 
in patients with HF; in fact, there were concerns that TNF- blockade may even be 
harmful. However, Douglas Mann has shown that too large concentrations of the 
TNF-antagonist etanercept could lead to a pooling-effect and continous relase of the 
targed cytokine43. Such effects might explain the lack of effect in HF patients treated 
with anti-TNF- therapies as etanercept. Despite recent studies suggesting positive 
effects of anti-inflammatory treatment in subgroups of HF patients44,45, the use of 
cytokines as therapeutic targets or as markers of cardiac disease is not considered to 
be a part of current clinical practice. The lack of success in this research field may 
also be related to the fact that many studies have been performed in heterogeneous 
patient populations with HF of varying aetiologies46. If cytokine activation differs 
according to the individual aetiology and form of HF, such approaches might not 
identify the correct targets or markers. 
Chemokines 
Chemokines are small (8-11 kDa) heparin-binding single polypeptide chemotactic 
cytokines (ranging from 70 to 100 amino acids). These cytokines are involved in the 
trafficking of leucocytes and play an important role in the control and regulation of 
leukocyte homeostasis in normal and diseased tissue. The chemokine superfamily is 
divided into four groups (CC, CXC, CX3C and XC), according to the two closely 
paired and highly conserved cysteine residues in their protein sequence47.
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Chemokines induce cell migration and activation by binding to specific G-protein–
coupled cell-surface receptors on target cells48,49. Four human CXC chemokine 
receptors (CXCR1 through CXCR4), eight human CC chemokine receptors (CCR1 
through CCR8), and one human CXXXC chemokine receptor (CX3CR1) have been 
identified. Chemokines also exert diverse biological effects on other cell types such 
as endothelial cells, fibroblasts, vascular smooth muscle cells, and cardiomyocytes. 
CXCL13/CXCR5 
CXCL13 (B lymphocyte chemoattractant (BCL)/B-cell attractant chemokine-1
(BCA-1)) are constitutively expressed within secondary lymphoid organs and 
regulate lymphocyte and dendritic cells homing to these organs50-52. CXCL13 is 
thought to be the only ligand for CXCR5, which was formally known as BLR153.
Expression of CXCR5 has been detected on mature recirculating B cells, a small 
subset of CD4+ and CD8+ T cells, and skin-derived migratory dendritic cells54-56.
CXCL13 is expressed by follicular dendritic cells and other stromal cells located in 
the B-cell regions of secondary lymphoid organs51,57. CXCR5 is essentially 
responsible for guiding B cells into B-cell regions of secondary lymphoid organs. 
However, CXCR5 expression in a subset of T cells strongly suggests a role for this 
receptor in T-cell migration as well. Thus, while CXCL13 is known to dictate 
homing and motility of B cells in lymphoid tissue, more recent studies suggest that 
CXCL13 is also involved in the formation of ectopic lymphoid tissue in chronic 
inflammation58. In line with its newly discovered role in the immune system, 
CXCL13 has been suggested to be involved in the pathogenesis of rheumatoid 
arthritis59, Sjögren syndrome60-62, inflammatory bowel disease63, and multiple 
sclerosis64.
Chemokines and heart failure 
There is growing evidence to suggest that chemokines and their receptors play an 
important pathogenic role in various cardiovascular disorders and in various forms of 
myocardial failure65-67. In patients, increased serum levels of CXCL1, CXCL5 and 
CXCL8 have been found in chronic congestive HF resulting from both ischaemic 
and nonischaemic cardiomyopathy; as would be expected, the highest levels are 
present in those with the most advanced disease68. Further, enhanced expression of 
CCR2 and CXCR4 has been observed in the failing human myocardium69. Our group 
has recently shown increased levels of the chemokines CXCL1670 and CX3CL171 in 
experimental and clinical HF. However, the potential mechanism of action for 
chemokines in HF is far from clear, and it is important to ascertain if these mediators 
have beneficial or protective effects. 
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Aims of the study 
The aim of this thesis was to analyse the role of cytokines and chemokines in 
myocardial hypertrophy and HF. 
The specific aims of the separate studies were to:
Paper I: To examine alterations in circulating cytokine levels in cardiac disease with 
different aetiologies and to relate cytokine activation to differences in 
pathophysiology. 
Paper II: To analyse the role of the chemokine CXCL13 and its receptor CXCR5 in
cardiac remodelling and development of HF, based on their roles in inflammation 
and extracellular matrix remodelling. 
Paper III: 
i) To identify chemokines which are regulated during RV pressure overload.
ii) To ascertain the contribution of these chemokines to myocardial remodelling
during RV overload through modulation of SLRPs. 
Paper IV: To ascertain the involvement of SLRPs in cardiac remodelling and reverse 
remodelling in aortic stenosis (AS) and aortic valve replacement, based on their roles 
in fibrogenesis and inflammation. We sought to analyse the role of the SLRPs,
decorin and lumican, and enzymes responsible for synthesis of their 
glycosaminoglycan (GAG) chains in a well characterised banding-debanding mouse
model.
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Summary of results 
Paper I:  
The main findings were: 
(1) No increase in circulating levels of cytokines in mice seven days after aortic 
banding (AB).
(2) In contrast, we found that the levels of four cytokines (IL--6, G-CSF, and 
monocyte induced by gamma interferon (MIG), also known as CXCL9) were 
increased after pulmonary banding (PB) compared to sham-operated mice. 
(3) In a group of myocardial infarction (MI) mice without HF, there were no
alterations in circulating cytokine levels, except for increased IL-18 levels; this effect
was even more pronounced in the HF group. 
(4) In SERCA2KO mice seven weeks after gene deletion, the levels of 12 cytokines 
were increased. Similar to findings in PB with HF mice, levels of IL--6, and G-
CSF were increased in the SERCA2KO mice. Levels of IL-12p40 were also
increased in this group, in contrast to the decreased values seen in all other HF 
groups examined. IL-2, IL-3, IL-9, IL-10, eotaxin, interferon (IFN)-	

chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-
also showed increased levels. 
Paper II:  
The main findings were: 
(1) Mice harbouring a systemic knockout of the CXCR5 gene (CXCR5 -/-) displayed 
increased mortality during a follow-up of 80 days after AB. 
(2) Following three weeks of AB, CXCR5 -/- developed significant LV dilatation
compared to wild type (WT) mice. 
(3) Microarray analysis revealed altered expression of several SLRPs that bind to 
collagen and modulate fibril assembly.
(4) Protein levels of fibromodulin, decorin and lumican (all SLRPs) were 
significantly reduced in AB CXCR 5-/- compared to AB WT mice. 
(5) Electron microscopy revealed loosely packed ECM with individual collagen 
fibrils and small networks of proteoglycans in AB CXCR5 -/- mice. 
(6) The addition of CXCL13 to cultured cardiac fibroblasts enhanced the expression 
of SLRPs.
(7) In patients with HF, we observed increased myocardial levels of CXCR5 and 
SLRPs, which was reversed following LV assist device treatment. 
Paper III:  
The main findings were: 
(1) Increased expression of several chemokines in RV following PB.
(2) Enhanced effect of CXCL16, CX3CL1 and CCL5 on mRNA levels of several 
SLRPs in myocardial fibroblasts. 
(3) Increased post-translational modification of decorin and enhanced protein levels 
of glycosylated lumican in RV following PB.
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(4) Enhanced effects of CXCL16, CX3CL1 and CCL5 (only lumican) on protein 
levels of glycosylated decorin and lumican in myocardial fibroblasts.
(5) Increased plasma levels of CXCL16 in clinical (pulmonary stenosis) and 
experimental (PB) RV failure.
Paper IV:  
The main findings were: 
(1) Increased protein levels of glycosylated decorin in the LV of mice after AB, 
together with increased expression of several CS/DS GAG chain synthesizing 
enzymes. 
(2) A gradual decrease in the glycosylated protein levels of decorin and certain 
CS/DS GAG synthesizing enzymes (i.e., chondroitin sulfate synthase -1 and -3
(CHSY-1 and -3)) in the LV after DB.
(3) Upregulation of one of these CS/DS enzymes, namely chondroitin polymerising 
factor (CHPF), in cardiac fibroblasts after CXCL16 stimulation. 
(4) Increased protein levels of lumican core protein with N-linked oligosaccharides, 
in the LV of mice after AB, which were decreased after debanding (DB).
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Methodological considerations 
Patients and healthy controls 
The patients included in Paper II were recruited from the Department of Cardiology 
at Oslo University Hospital, Rikshospitalet, Oslo, Norway. The aetiology of HF was 
classified as coronary artery disease or dilated cardiomyopathy based on disease 
history, echocardiographic examinations and coronary angiographic examinations. 
All patients had NYHA class IV HF. Eight were male and one was female, and the 
mean age was 29±5 years. LV tissue was available at the time of implantation and at 
the time of removal (heart transplantation) of a continuous-flow LV assist device 
(LVAD; EntrAssist, Ventracor Ltd, Chatswood, Australia). Average time on LVAD 
was 8.0±1.7 months. Control (non-HF) human LV tissue was obtained from subjects
whose hearts were rejected as cardiac donors for surgical reasons (n=5). The cause of 
death of donors was cerebrovascular accident, and none had a history of heart 
disease. To keep confounding factors to a minimum, patients with other
accompanying conditions known to modulate inflammation (e.g., autoimmune 
diseases, infections, malignancies, or connective tissue diseases) were excluded from 
the study. In Paper III, the patients were recruited from the Department of Paediatrics
at Oslo University Hospital, Rikshospitalet, Oslo, Norway. Nine patients (4 male, 5 
female, mean age 64 months (range, 2-186 months)) were recruited after referral to a 
tertiary clinic for first-time or follow-up control of moderate to severe pulmonary 
stenosis. Four of the patients underwent catheterization of the RV for percutaneous 
balloon pulmonary valvuloplasty (BVP). All patients were evaluated by continuous 
Doppler echocardiography. Patients with a peak pulmonary valve velocity higher
than 3 m/s were included. This cut-off value was chosen because it represents a 
gradient above which balloon valvuloplasty can be considered. All patients had 
typical valvular pulmonary stenosis. There were no associated cardiac defects in 8 
patients, but one patient had mild supravalvular aortic stenosis with a peak aortic 
valve velocity amounting to 2.0 m/s. The same patient had Williams syndrome. Two 
patients had mild to moderate pulmonary regurgitation. None had clinical signs of 
right ventricular failure. Exclusion criteria included signs of infection at clinical 
examination and/or serum levels of C-reactive protein (CRP) >10 mg/L. Healthy 
children of hospital staff (n=4), and a group of children with nevus flammeus without 
additional chronic illness (n=5) served as control subjects. All controls (mean age 53 
months (range, 12-146 months)) had CRP levels <10 mg/L. 
Blood sampling for chemokine measurements 
One purpose of this thesis was to study cytokine and chemokine levels in plasma 
from HF patients and children with pulmonary stenosis, as well as in serum from PB, 
AB and MI mice and controls. Several factors related to blood collection and 
processing may influence the measured chemokine levels in plasma and serum. 
Recovery of chemokines in blood samples is known to be reduced over time after 
blood collection, particularly if the samples are not stored at 4oC before separation72.
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Therefore, in all our experiments, blood samples were immediately immersed on 
melting ice before processing.
Animal models 
The use of mice as experimental animals has several benefits in that they are small, 
inexpensive, well characterized and able to be genetically modified. Although there 
are obvious major phenotype differences, such as size, tail, ear, fur and bilateral 
venae cavae superior, 99% of mouse genes have a detectable human homolog73.
There are also physiological differences, e.g. basal heart rate, which is about 600-700 
bpm in mice74 and 60-70 bpm in man. Mice, however, are a desirable model for 
comparative medical research as the mouse genome has been sequenced and 
transgenic and knockout techniques have been developed73. In all papers in this 
thesis, C57BL/6 mice and genetically modified animals on a C57BL/6 background 
were used. We used several different experimental models of HF in mice (Figure 1):
banding and debanding of the ascending aorta, pulmonary artery banding and 
ligation of the left coronary artery.
Figure 1. Experimental models of heart failure in mice. (A) aortic banding, (B)
aortic debanding, (C) pulmonary artery banding, (D) ligation of the left coronary 
artery. 
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Ligation of the left coronary artery and banding of the ascending aorta, are described 
in detail in Paper I, II and IV and elsewhere75,76. The banding-debanding model is 
described in detail in Paper IV and elsewhere77,78. Banding of the pulmonary artery is 
described in Paper I and elsewhere74,76. In Paper I we also used a genetically 
modified mouse line that develops HF after deletion of the sarco(endo)plasmic 
reticulum Ca2+-ATPase2 gene induced by tamoxifen treatment, known as the 
SERCA2KO mice. The generation of SERCA2KO and SERCA2FF (control) mice 
has been described in detail elsewhere79. Mice were euthanised 4 (SERCA2KO4w) 
and 7 (SERCA2KO7w) weeks after the initiating tamoxifen treatment. The 
generation of CXCR5-/- mice used in Paper II (C57BL/6 background, now accessible 
at the Jackson Laboratory, stock number 006659, strain name B6.129S2 (Cg)-
Cxcr5tm1Lipp/J) has been described in detail elsewhere80. For surgical procedures, all
animals were anaesthetised and ventilated with a mixture of 2% isoflurane and 98 % 
oxygen. Most types of anaesthesia will affect cardiac function to a certain degree, 
rendering the conditions under which the examination is carried out somewhat un-
physiological. However, by standardising and optimising the anaesthesia as much as 
possible, one is at least able to examine relative differences between groups. Since all 
operations on mice were rather extensive, it is obviously always necessary to 
compare the responses to sham-operated animals, in order to be able to exclude the 
effects of the operation itself. Banding of the aorta and the pulmonary artery is 
achieved rather quickly compared to the natural development of an aortic or 
pulmonary stenosis, which the procedure is intended to imitate, wheras ligation of 
the left coronary artery is more comparable to an acute infarction with regard to 
time-course. However, it may be argued that the pathogenesis is not analogous to that 
of atherosclerotic coronary disease and MI in humans, given that the mice have 
otherwise healthy coronary arteries. Nevertheless, the coronary artery ligation and 
banding models have been shown to be valid models for investigation of myocardial 
hypertrophy81.
Echocardiography 
Echocardiography is a non-invasive method that can provide serial and detailed 
information about in vivo cardiac function. The method is described in all papers. 
There are several concerns regarding mouse echocardiography. The collection of 
echocardiographic recordings requires great skill82; of note, all recordings used 
herein were performed by one operator. In mice, the high heart rate and short 
working distance represents a technical challenge. We used a fully digital system 
with modified software that allowed sufficient time resolution for reliable end-
systolic and -diastolic measurements. A Q 13 M-Hz linear array transducer designed 
for the examination of small rodents was also used, giving a sufficiently short 
working distance. The data were analysed with a VIVID 7 echocardiograph (GE 
Vingmed Ultrasound, Horten, Norway). 
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Histology and immunohistochemistry 
When interpreting histological and immunohistological sections, one must take into 
account that these methods are only semiquantitative. Cutting sections as thin as 5 
µm is fraught with pitfalls, including folding of the sections, tearing of thin structures 
and appearance of lines and distortions due to the use of uneven or blunt knives. The 
methods used for fixation, staining and antibody incubation can also distort the 
morphology and organization of the tissue to be examined to a certain degree. 
Staining of sections can be uneven. Finally, the antibodies used for 
immunohistochemistry can be of varying quality with regard to specificity. All 
samples were interpreted by two pathologists who were blinded for genotype and 
intervention. 
Transmission electron microscopy 
Considering the minute dimensions, slicing of sections is a considerable challenge. 
The correct interpretation of findings is dependent on considerable experience and 
knowledge within the field. 
Array screening 
Microarray screening is a technological development that allows for simultaneous 
analysis of expression of multiple genes. The Affymetrix Gene Chip analyses over 
39,000 transcripts on a single array. The processing of microarray data has been 
refined and open source software is shared in the scientific community trough 
BioConductor (http://www.bioconductor.org/). The substantial amount of data 
generated from microarray screening, however, can be confusing and difficult to 
interpret. The large number of analyses also represents a statistical concern, as a level 
of significance of p=0.05 just by chance would generate 5 positive tests out of 100 
performed. Thus, 39,000 tests would by chance generate 1950 positive tests. There 
are statistical methods to correct for multiple testing. The false discovery rate (FDR) 
is the expected rate of false positive results in an analysis of multiple genes, and 
statistical methods to estimate FDR have been developed and represent important 
tools in the analysis of microarray data83. We have therefore collaborated closely 
with statistical experts in the field of bioinformatics. The cost of gene chips is rather 
high, which usually leads to a rather small number of animals included in microarray 
studies. Important findings must be verified either on the transcriptional level (e.g. by 
qPCR) or by protein analysis. 
RT-qPCR 
Real-time quantitative polymerase chain reaction (RT-qPCR) is a method to analyse
expression of individual genes by determining levels of mRNA with a particular 
genetic sequence in a specimen84-86. This technique is now widely used to quantify 
mRNA. Following mRNA isolation, reverse transcriptase is used to create 
complementary DNA (cDNA), as mRNA is an unstable molecule. As for all methods 
that require isolation of RNA it is very important to avoid degradation of the material 
22
by immediate snap freezing, as well as repeated freezing and thawing cycles. 
Treatment with DNase is necessary in order to avoid false DNA signals in the assay. 
Likewise, varying quality of the RNA obtained can result in false differences in 
observed amount of PCR product. In our experiments the RNA quality was evaluated 
using bioanalyser (Agilent) producing a RIN value (RNA Integrity Number). Only 
samples with high integrity and purity were used in our experiments (absorbance 
ratio>1.8). A small amount of tissue yields sufficient mRNA to perform multiple RT-
qPCR analyses. The accumulation of PCR-product was monitored for each cycle 
using fluorescent probes (TaqMan). The specificity of primers and probes used is 
naturally also of great importance. In our experiments we used primers and probes 
with high specificity, and for comparisons of results obtained from different 96 well 
plates we made sure to normalize against an endogenous control (RpL4 or GAPDH), 
which was run on the same plate at the same time. Ideally, the control genes should 
not be regulated in the tissue or cells investigated, and the interindividual variation 
should also be low. In our experiments, housekeeping genes and the relative 
expression were stable between samples within the same experiment. 
Western blotting 
While analysis of gene expression may be used as a marker of protein synthesis, 
Western blotting (immunoblotting) is an analytic technique used to determine protein 
levels87,88. Briefly, proteins are isolated from tissue specimens, separated by size 
using gel electrophoresis, transferred to a membrane and detected using specific 
antibodies, visualized by chemiluminescence and quantified by densitometry. 
Membranes were reprobed with actin, vinculin or GAPDH as protein loading 
controls. Good antibody quality is very important if false negative and false positive 
results are to be avoided. In the case where the number of samples is so high that 
they have to be run on two different gels, it is essential to have a sufficient number of 
the same samples on both gels enabling normalization between the two. 
Enzyme linked immunosorbent assays (ELISAs) 
Enzyme-linked immunosorbent assay (ELISA) is another technique for protein 
analysis72,89. We have used commercial kits as part of the “sandwich ELISA” 
technique. Briefly, the kit contains a microplate pre-coated with antibody specific for 
the protein to be analysed. Standards and samples are applied and unbound
substances are washed away. An enzyme-linked protein specific antibody is added to 
the wells, the plate is washed and a solution with chemical being converted to colour 
by the enzyme is applied. The intensity of the colour is measured. The intensity of 
each sample is related to the standard curve, which gives the concentration of the 
protein of interest in the specimens. Antibody specificity is of course important also 
in this technique. 
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Bio-Plex protein assay system based on xMAP technology from 
Luminex 
A Bio-Plex protein assay is a multiplex protein assay that allows for simultaneous 
examination of multiple proteins in a sample90. The technology is based on a family 
of fluorescently dyed microspheres or beads from Luminex Corp., the use of a 
special flow cytometer to measure the reactions occurring in the surface of the beads 
and a high-speed digital signal processor to manage the fluorescent output. Antibody 
specificity is of high importance in this technique. While proteins are separated by 
size in Western blot, this is not the case with multiplex and ELISA analysis, thus 
antibody specificity is even more important for both these techniques than for 
Western blot. 
Isolation and culturing of myocardial-derived cells 
Cardiomyocytes and cardiac fibroblasts were isolated from the LV as described by 
Wollert et al, using tissue digestion and subsequent centrifugation of the cell 
suspension through a discontinuous Percoll gradient91. This procedure yields 
cardiomyocyte cultures with purity >92% as determined by staining of nuclei and F-
actin using Hoechst dye and Oregon Green 488, respectively92. Notably, the 
percentage of cardiomyocytes did not change during the experiments, indicating an 
absence of proliferative cells in the cultures. Cardiomyocytes and cardiac fibroblasts 
isolated from immature animals such as neonatal rats are the most commonly used 
cells for the study of pathological events at a cellular level, such as myocardial 
hypertrophy and ECM remodeling93. Neonatal cells are often preferred over to adult 
cells for several reasons. First, neonatal cells are easier to culture than the adult type. 
Adult cardiomyocytes are larger and grow more slowly in vitro. Second, when 
subjected to hypertrophic stimuli, neonatal cells in culture react with characteristic 
changes in gene expression similar to those found in adult cardiomyocytes in vivo.
Adult cardiomyocytes and cardiac fibroblasts are derived from terminally 
differentiated heart tissue, and it is these cells that in vivo are subjected to pathogenic 
stimuli. Therefore, it may be argued that adult cells in vitro may be a more accurate 
model for the in vivo situation than neonatal cells. However, although the model has 
it limitations, neonatal cardiac cells represent a very useful tool for the in vitro
elucidation of potential pathogenic consequences of over- and underexpression of 
mediators such as cytokines and chemokines. 
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General discussion 
Cytokine response in cardiac diseases 
The aim of Paper I was to examine whether alterations in circulating cytokine levels 
are dependent on the aetiology of myocardial hypertrophy and HF. The key results in 
Paper I were that increased serum levels of several cytokines were found in mouse 
models with increased RV afterload under PB and SERCA2KO7w conditions. In 
common for PB and SERCA2KO7w conditions was the presence of systemic 
congestion, suggesting that this is a stimulus for cytokine release into the circulation.
Increased cytokine levels associated with systemic congestion indicate the possibility 
of an extracardiac source of cytokine release.  This finding seem to be concordance 
with the endotoxin hypothesis, which suggests that oedema of the intestines in right-
sided HF induces translocation of endotoxins into the systemic circulation94. Then, in
the bloodstream, endotoxins may activate monocytes to release cytokines, resulting 
in increased cytokine concentrations95. Surprisingly, in mice with pulmonary 
congestion (AB and MI), several cytokines showed unaltered or even decreased 
levels in the circulation. Previous studies have shown increased levels of cytokines in 
heart disease of these aetiologies68,96,97. However, the increase in cytokine levels 
found in such animal and human studies may be caused by systemic congestion 
following RV failure. 
The role of chemokines in cardiac remodelling 
Despite the observed enhanced levels of chemokines in experimental and human 
HF68-71, the role of chemokines in cardiac remodelling is far from clear. It is of great 
importance to acknowledge if these mediators have a pathogenic role in the 
development and progression of HF rather than a beneficial or protective effect. The 
key results in Paper II were that there was increased mortality and severe LV 
dilatation in CXCR5-deficient mice in response to LV pressure overload, potentially 
resulting from ECM alterations that derived from decreased SLRP levels in the 
myocardium. We found that CXCL13 promotes SLRP expression in cardiac 
fibroblasts. In Paper III we found that several chemokines upregulated in the 
pressure-overloaded RV (CXCL16, CX3CL1 and CCL5) also upregulated the 
expression of SLRPs in cardiac fibroblasts. The same chemokines did also enhance 
the glycosylated protein levels of decorin and lumican in cardiac fibroblasts medium. 
In Paper II, III and IV we note the presence of a glycosylated form of decorin, a 
chondroitin/dermatan sulfate (CS/DS) proteoglycan, with a higher molecular weight
in the pressure-overloaded right and left ventricles compared to control mice. In 
Paper IV we showed that CXCL16 regulates the expression of chondroitin 
polymerizing enzyme (CHPF), one of the enzymes responsible for CS/DS GAG 
polymerization. 
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CXCL13/CXCR5 in cardiac remodelling 
Expression of CXCL13-CXCR5 in the heart 
Before the present reports, the only reports on CXCL13 or CXCR5 in the heart were 
in cardiac allografts. Increased CXCL13 expression has been found within the 
transplanted allograft compared to native hearts, but the source of CXCL13 in the 
allograft was not known98. The same study showed increased expression of CXCR5 
on regulatory T cells in the heart. Others have shown features of tertiary lymphoid 
tissue in cardiac allograft and increased expression of CXCL13-CXCR5 in 
lymphocytes and macrophages99. In Paper II, we showed that both CXCL13 and 
CXCR5 were expressed in the murine heart. We found significantly increased 
myocardial expression of CXCR5, but not CXCL13 in AB mice compared to sham 
operated mice. Within the myocardium, we found mRNA expression of CXCR5 and 
CXCL13 in cardiomyocytes, fibroblasts and endothelial cells, with the highest 
expression found in myocardial fibroblasts. Assessment of CXCR5 mRNA levels in 
myocardial tissue from HF patients showed markedly enhanced gene expression of 
CXCR5. Production of CXCL13 and CXCR5 in myocardial tissue has, to the best of 
our knowledge, not previously been demonstrated. 
Cardiac phenotype of CXCR5-/- mice following LV pressure-overload 
In Paper II, we studied the role of CXCR5 in a knockout model of CXCR5. Others 
have studied this knockout model and found it viable, but having decreased Payers 
plaques and lymph nodes54. However, the hearts in these mice have never been 
studied. Our analysis revealed a clear phenotype with significant dilatation and wall 
thinning of the pressure-overloaded LV. Increased LV volume induces excessive 
wall stresses that are believed to impair contractile function and trigger maladaptive 
cardiac remodelling leading to development of overt HF100. Increased expression of 
-MHC genes suggests increased myocardial wall stress in these 
mice. One working hypothesis of HF is that loss of cardiomyocytes by apoptosis 
leads to progressive ventricular dysfunction of the heart101,102. Myocardial apoptosis 
may be directly related to progressive wall thinning and failing pump function103-106.
Apoptosis may play a causative role in the phenotype of LV dilatation and wall 
thinning of AB CXCR5-/- mice. We did not find any increase in apoptosis using in 
situ TUNEL (Terminal dUTP nick end labeling) analysis. However, quantification of 
apoptosis is difficult as histochemical visualization of nuclear DNA fragments by 
TUNEL has limited specificity101,107. Ventricular overload can result in myocardial 
inflammation as demonstrated by myocardial expression of proinflammatory 
cytokines and leukocyte infiltration into the myocardium40,108. As CXCL13 is one of
the most potent B-cell chemoattractants52 and plays an important role in 
inflammatory diseases52,109-111, we hypothesized in Paper II that CXCL13 and 
CXCR5 could also be important in myocardial inflammation. Surprisingly, we did 
not find any changes in infiltration of CD3 or CD45 positive cells by 
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immunohistochemistry. However, our data showing a markedly dilated myocardial 
phenotype in CXCR5 -/- mice exposed to pressure overload, without any significant 
changes in apoptosis or myocardial leukocyte infiltration, suggest direct involvement 
of CXCL13/CXCR5 activation on ECM remodelling.
CXCL13/CXCR5 in ECM remodelling 
Collagen network in CXCR5 -/-mice following LV pressure-overload 
Recently, it has been reported that CXCR5 is involved in remodelling of the ECM in 
various types of cancer, including colon112 and prostate cancer113. Perhaps the most 
widely recognized alteration that occurs in the ECM in the failing heart is the 
development of fibrosis114. In Paper II we examined the quality and composition of 
the collagen in CXCR5 -/- mice following AB. These mice exhibited increased 
myocardial collagen content following AB compared to WT mice, as illustrated by 
both Masson trichrome staining and hydroxyproline measurement by HPLC. The 
deposition of collagen (increased total collagen) is a classical response to tissue 
injury and an accumulation of myocardial collagen can be seen diffusely in cases of
myocardial fibrosis of pressure overload16,115. Although we observed increased total 
collagen content in CXCR5-/- mice, these mice were also characterized by massively 
disturbed structural frameworks after AB. Electron microscopy revealed loosely 
packed ECM with individual collagen fibrils in AB CXCR5-/- mice. Other studies 
indicate that the normal collagen weave is considerably disrupted and degraded in 
failing myocardium, and that levels of myocardial collagen fibres decrease and the 
fibres show reduced thickness. For example, in patients with end-stage dilated 
cardiomyopathy, the collagen network was reduced in parallel to LV dilatation21.
MMPs in CXCR5 -/-mice following LV pressure-overload 
MMPs represent an important family of enzymes capable of degrading the ECM116.
Enhanced MMP activity and in particular increased activity of MMP-2 and MMP-9, 
plays an important role in myocardial remodelling, contributing to the development 
of myocardial failure 117. The increase in collagen content in CXCR5 -/- mice was 
accompanied by a significant increase in total MMP activity and gelatinolytic 
activity of MMP-2 and MMP-9. At the level of MMP gene expression and secretion
into the ECM, cytokines and other growth factors that are known to be increased in 
the failing heart have also been identified as important physiological MMP gene 
inducers25. In particular, proinflammatory cytokines such as TNF- have been 
implicated in both MMP expression and the reduction of endogenous inhibitors that
leads to overall increases in MMP activity25,118. The effects of proinflammatory 
cytokines on ECM homeostasis via MMP expression and activity describe a possible 
mechanism by which the cytokine hypothesis of remodelling and failure is viable. 
Dahl et al.70 have shown that chemokines such as CXCL16 increase MMP activity in 
myocardial fibroblasts. However, in contrast to what others have shown in prostate 
cancer cells 113 and in oral squamous cells, 119 we showed in Paper II that CXCL13 
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decreases total MMP activity in myocardial fibroblasts. The combination of 
increased collagen content and increased MMP activity suggests enhanced matrix 
remodelling in CXCR5 -/- mice following AB.
Chemokines in RV remodelling 
In studies for Paper I, we found increased circulating levels of several cytokines in 
models with increased RV afterload, PB and SERCA2KO7w. In Paper III, we 
identified upregulated chemokines in the RV after pressure-overload. Right-sided HF 
is a major challenge in the increasing population of adults with congenital heart 
defects, but few studies have focused on the molecular changes leading to RV failure 
120. While a role for chemokines in LV failure has been established by demonstration 
of both elevated circulating and myocardial levels in patients with left-sided HF68-71,
little is known about the role of chemokines in right-sided HF. Indeed we found that 
several chemokines were upregulated in the RV under such conditions. Microarray 
analysis (Affymetrix) of RV tissue from mice with PB revealed that CXCL10, 
CXCL6, CX3CL1, CCL5, CXCL16 and CCL2 were the most upregulated 
chemokines. These findings suggest that the inflammatory system is indeed also
involved in development of RV dysfunction.  
Potential mechanism of action of chemokines in heart failure 
Regulation of SLRPs  
Previously, it has been shown that TGF-!
and fibromodulin in different cell systems121-124. Also IL4, IL-6 and IL-10 are shown 
to upregulate decorin expression in human skin fibroblasts125-127. Il-"#-
have also been implicated in the regulation of decorin synthesis128. However, the 
influence of chemokines on the regulation of SLRPs had not been studied previously. 
Our findings indicate that chemokines could affect SLRPs synthesis both at a 
transcriptional level and at a post-translational level. 
Chemokines regulate mRNA expression and protein levels of SLRPs  
In Paper II, we showed that addition of CXCL13 to cultured cardiac fibroblasts 
enhanced the expression of SLRPs. In Paper III, we showed that several other 
chemokines, CXCL16, CX3CL1 and CCL5 increased the expression of the same 
SLRPs, namely decorin, lumican, biglycan and fibromodulin, by stimulation of 
cardiac fibroblasts. In the same paper we also showed that CXCL16, CX3CL1 and 
CCL5 (only lumican) enhanced the glycosylated protein levels of decorin and 
lumican in myocardial fibroblasts. These studies show, for the first time, that 
chemokines with increased expression in the heart tissue during pressure-overload 
can induce mRNA expression and enhance protein levels of SLRPs in cardiac 
fibroblasts. 
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Cytokines and chemokines affect SLRPs at a post-translational level 
In Paper II, III and IV we found an elongation of the CS/DS GAG chain of decorin 
after RV and LV pressure-overload. The stimulus for this elongation has not been 
elucidated. Bassols et al.121 have shown that TGF-$
well as the molecular size of the CS/DS proteoglycans. In Paper IV, we investigated 
whether chemokines, CXCL16, CX3CL1 and CXCL13, shown to increase decorin 
expression and protein levels, also could control post-translational modification of 
the CS/DS GAG chain by regulating CS/DS GAG chain synthesizing enzymes. At 
least five enzymes generate the CS/DS polysaccharide of decorin, chondroitin 
polymerizing factor (CHPF)129, CS synthase (CHSY)-1, -3130 as well as CS N-
acetylgalactosaminyltransferase (CSGALNACT)-1, and -2131,132. CHPF, (CHSY)-1, -
3 and CSGALNACT-2 were shown to be upregulated in the left pressure-overloaded 
ventricle, indicating increased glycosylation and elongation of the CS/DS GAG chain 
of decorin. To the best of our knowledge an increase in these enzymes has never 
been shown in the pressure-overloaded heart. Interestingly, in Paper IV, after relief 
of the pressure overload by debanding (DB), CHSY-1 and -3 showed the same 
reduction in expression as was observed for glycosylated protein levels and the size 
of the GAG chain. CXCL16 increased the expression of CHPF in cardiac fibroblasts, 
indicating a possible mechanism for chemokine regulation of CS/DS GAG chain 
synthesis. However, future studies are required to precisely define the molecular 
mechanisms behind these effects and to outline the biological consequences. 
Figure 2. Synthesis of SLRPs is affected at two levels, both at a transcriptional and 
a post-translational level. (A)  CXCL16, CX3CL1, CCL5 and CXCL13 increase the 
mRNA exprssion of decorin, lumican, fibromodulin and biglycan. (B) CXCL16 
increases the expression of chondroitin polymerizing factor, CHPF, an enzyme 
important for chondroitin sulfate/dermatan sulfate (CS/DS) synthesis.
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The role of SLRPs in cardiac remodelling 
In Paper II, III and IV we found increased protein levels of the SLPRs, decorin and
lumican, in pressure-overloaded ventricles. In Paper IV we found a decrease in 
glycosylated decorin protein levels and lumican core protein with N-linked 
oligosaccharides after debanding. Together, these findings indicate a role for 
glycosylated decorin and lumican core protein in myocardial remodelling and reverse 
remodelling following AB and DB, respectively, which will be discussed in more 
detail below.
SLRPs as regulators of the collagen network 
SLRPs and the collagen network 
During the last two decades, SLRPs have been shown to bind collagen and modulate 
fibril assembly133. Disorganized collagen is seen in decorin knockout mice36. Null 
mutations of lumican81,134 and fibromodulin135 also lead to abnormal collagen 
architecture. Collagen fibrils in the ECM in AB CXCR5 -/- mice resemble the 
structure and organization seen in SLRP knockout mice. Binding of SLRPs to 
collagen fibrils, regulation of fibril diameter and lateral fusion all seem to be 
important for the architectural integrity of the collagen network133. We do not know 
at which level the SLRPs act to regulate collagen fibrils. Kalamajski et al.133 suggest 
that lumican may regulate the intermolecular cross-linking of collagen fibrils. Cross-
linking determines the mechanism and level of degradation of collagen fibrils, but no 
known mechanism for cross-link regulation has been found, except for the enzymatic 
activity of lysyl oxidase. Kalamajski et al.133 propose that, in the absence of lumican,
misalignment of collagen fibrils may appear that in turn could lead to improper or 
failed cross-linking thereby affecting fibril diameter. Reduction in collagen cross-
links has been demonstrated in human dilated cardiomyopathy with LV 
dilatation18,20. In addition, pharmacological inhibition of collagen cross-linking 
increases myocardial compliance, leading to LV dilatation136. Accordingly, the 
degree of collagen cross-linking may have significant impact on myocardial 
remodelling.
Role of decorin during pressure-overload 
As mentioned previously, in pressure-overloaded RV and LV tissue, Western 
blotting revealed a glycosylated form of decorin with a higher molecular weight 
compared to control mice. Changes in the size of the GAG chain of decorin, DS or 
CS, have been found in a variety of tissues such as skin during wound healing137 and 
post-burn hypertrophic scars138. Kuwabe et al.139 showed that CS/DS GAG chains 
oriented orthogonally to collagen fibrils were longer in healing skin than in control 
skin. Electron microscopy revealed that CS/DS GAG chains were found among 
tightly packed collagen fibrils in control skin. In contrast, the interfibrillar gaps 
between each collagen fibril were enlarged in healing skin and elongated CS/DS 
GAG chains extended from the surface of collagen fibrils across enlarged gaps. 
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These results suggest that the increase in molecular size of the CS/DS GAG chain is 
important to the organization of collagen fibrils separated by enlarged interfibrillar 
gaps in healing skin. It is tempting to speculate that an elongation of the decorin 
CS/DS GAG chain also increases the distance between collagen fibrils in the 
pressure-overloaded heart. It is unknown if this is beneficial, to secure the stability 
and strength of the collagen network during pressure-overload, or in contrast,
reducing the strength and forcing a dilatation of the ventricle. However, our studies 
demonstrate that the size of the GAG chain of decorin is regulated in pressure-
overloaded ventricles and reduced to normal size after pressure relief, possibly 
contributing to the arrangement of collagen fibrils in remodelled cardiac tissue. 
SLRPs as signaling molecules and regulators of inflammation 
SLRPs and Toll-like receptors 
Initially thought to act exclusively as structural components, SLRPs are now 
recognized as key players in cell signaling and in inflammatory responses33.
Recently, soluble biglycan has been shown to be a proinflammatory signaling 
molecule acting as an endogenous ligand of the innate immunity receptors, Toll-like 
receptors (TLR)-2/4 on macrophages140,141. By binding to TLR2 and TLR4, biglycan 
increases the expression of proinflammatory cytokines such as TNF-
$
inflammatory protein (MIP)-2, MCP-1, RANTES and CXCL13 and pro IL-141-143.
This causes further recruitment of new macrophages, which in turn stimulates
production of biglycan, creating a feed-forward cycle that is capable of driving the 
inflammatory response. Thus, biglycan can boost inflammation by signaling through 
TLR2 and TLR4. Lumican is involved in the presentation of bacterial 
lipopolysaccharides to CD14, thereby activating TLR4144. Recent clinical and 
experimental studies suggest that TLRs may play an important role in the 
development and progression of HF. Frantz et al.145 were the first to report the 
existence of TLR4 expression in human and rodent hearts. Increased myocardial 
TLR4 expression was noted in tissue sections from hearts of humans with ischemic 
cardiomyopathy and of rodents with experimental HF. Using TLR2-deficient mice, 
Shishido et al.146 reported a significant reduction in mortality and LV dysfunction 
after coronary artery ligation. These experimental data suggest that TLR 2 and TLR4 
may be viable targets for the treatment of HF. The question that remains unanswered 
is whether it will be possible to modulate the consequences of TLR activation in the 
heart through blockade of SLRPs (i.e. biglycan and lumican), and what the effects of 
such interventions during hypertrophy and transition to HF induced by pressure-
overload may be.
SLRPs regulate the activity of cytokines and chemokines 
Another mechanism whereby SLRPs regulate the inflammatory response in tissues is 
by interaction with cytokines and chemokines. Decorin, biglycan and fibromodulin 
31
can interact with several cytokines such as TGF-147, TNF-148, Wnt-1-induced 
secreted protein 1 (WISP-1)149 as well as IL-8, a member of the CXC chemokine 
family150. By binding these cytokines, SLRPs can modulate their activity. 
Furthermore, SLRPs may mediate neutrophil infiltration by forming an immobilized 
chemokine gradient within inflamed tissues151.
Effects of SLRPs on TGF-	 
A great deal of attention has been focused on the antifibrotic properties of decorin as 
a neutralizing factor affecting TGF-%&$"'#-markedly increased in 
both right and left ventricular overload, and decorin might very well have an 
antifibrotic effect in cardiac remodelling by neutralizing TGF-(%#!!
SLRPs may regulate ECM remodelling by modulating MMP activity thereby 
affecting collagen fibrils. The work by Geng et al.152 demonstrate that the interaction 
of decorin, fibromodulin and lumican at the surface of either type I or type II 
collagen fibrils can diminish the susceptibility of the collagen fibrils to both MMP1 
and MMP13 cleavage. In the pressure-overload situation, with increased MMP 
activity, the protective function of SLRPs during stabilization of newly formed 
collagen fibrils may be of great importance. 
Figure 3. Proposed function of SLRPs in cardiac remodelling during pressure 
overload. (A) CXCL13, CXCL16, CX3CL1 and CCL5 bind to their respective 
receptors on cardiac fibroblasts and increase mRNA expression of decorin, biglycan, 
fibromodulin and lumican, and alter the protein levels of (B) lumican and (C)
decorin. (D) Decorin is capable of neutralizing the activity of TGF-	
	
antifibrotic effect. (E) Decorin binds to collagen fibrils and helps to stabilize the 
collagen network and (F) protects the collagen fibrils from cleavage by MMPs. (G)
Lumican might activate TLR on machrophages and induce an inflammatory respons.
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Future perspectives 
There remain many unanswered questions about the role of chemokines in HF. The 
possible role of chemokines in cardiac remodelling during pressure-overload is quite 
intriguing, as are the direct effects stemming from interaction of chemokines with 
SLRPs. The control of ECM remodelling by chemokines in the failing heart could 
provide a missing link in our currently inadequate pathophysiological understanding;
in addition, a better understanding of the complex role of SLRPs in the normal and 
failing myocardium may facilitate the development of targeted anti-remodelling
strategies. For instance, anti-SLRP treatment may be beneficial in blocking the 
consequences of TLR activation in the heart. On the other hand, we believe that an 
increase in the protein level of SLRPs is important for maintenance of normal
collagen architecture during pressure-overload. Thus, the question of whether 
blocking of SLRPs will be beneficial or not remains unanswered. Future goals of our
laboratory include further studies on these topics. Knockout mouse models showing
overexpression of specific chemokines, such as CXCL16 and CX3CL1, as well as 
SLRP knockout mice would be extremely valuable to further address the possible 
role of chemokines and SLRPs in cardiac remodelling.
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Conclusions 
Paper I: 
In conclusion, serum levels of cytokines in mice with heart disease are highly 
dependent on the aetiology and pathophysiological alterations in the heart and 
circulation. Increased serum levels of several cytokines were found in models with 
increased right ventricular afterload, suggesting that systemic congestion is an 
important stimulus for cytokine release into the circulation in HF. 
Paper II:
A lack of CXCR5 leads to LV dilatation and increased mortality during pressure 
overload, possibly due to the lack of an increase in SLRPs. This study demonstrated
a critical role of CXCL13 and CXCR5 in survival and maintenance of cardiac 
structure in pressure-overload conditions through regulation of proteoglycans 
essential for correct collagen assembly.
Paper III: 
We found that chemokines are upregulated in the pressure-overloaded RV and that 
CXCL16, CX3CL1 and CCL5 regulate expression and post-translational 
modification of SLRPs in cardiac fibroblasts. In the pressure-overloaded RV, protein 
levels of lumican were increased, and a glycosylated form of decorin with a high 
molecular weight was also present.
Paper IV:
Our findings suggest a role for glycosylated decorin and N-glycosylated lumican 
core protein in myocardial remodelling and reverse remodelling following AB and 
DB, respectively. Moreover, several CS/DS GAG chain synthesizing enzymes are 
upregulated in the pressure-overloaded LV corresponding to the increased levels of 
glycosylated decorin; notably, levels of two of these enzymes (CHSY-1 and -3) 
decrease during DB, suggesting a role for these enzymes during reverse remodelling.
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Abstract
Rationale: Inflammatory mechanisms have been suggested to play a role in the development of heart failure (HF), but a role
for chemokines is largely unknown. Based on their role in inflammation and matrix remodeling in other tissues, we
hypothesized that CXCL13 and CXCR5 could be involved in cardiac remodeling during HF.
Objective: We sought to analyze the role of the chemokine CXCL13 and its receptor CXCR5 in cardiac pathophysiology
leading to HF.
Methods and Results: Mice harboring a systemic knockout of the CXCR5 (CXCR52/2) displayed increased mortality
during a follow-up of 80 days after aortic banding (AB). Following three weeks of AB, CXCR52/2 developed significant
left ventricular (LV) dilatation compared to wild type (WT) mice. Microarray analysis revealed altered expression of several
small leucine-rich proteoglycans (SLRPs) that bind to collagen and modulate fibril assembly. Protein levels of
fibromodulin, decorin and lumican (all SLRPs) were significantly reduced in AB CXCR52/2 compared to AB WT mice.
Electron microscopy revealed loosely packed extracellular matrix with individual collagen fibers and small networks of
proteoglycans in AB CXCR52/2 mice. Addition of CXCL13 to cultured cardiac fibroblasts enhanced the expression of
SLRPs. In patients with HF, we observed increased myocardial levels of CXCR5 and SLRPs, which was reversed following
LV assist device treatment.
Conclusions: Lack of CXCR5 leads to LV dilatation and increased mortality during pressure overload, possibly via lack of an
increase in SLRPs. This study demonstrates a critical role of the chemokine CXCL13 and CXCR5 in survival and maintaining of
cardiac structure upon pressure overload, by regulating proteoglycans essential for correct collagen assembly.
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Introduction
Heart failure (HF) is a disorder associated with low-grade
immune activation and inflammation, as evidenced by elevated
circulating and myocardial levels of inflammatory cytokines,
including tumor necrosis factor (TNF)a, interleukin (IL)-1b and
IL-18, and chemokines such as monocyte chemoattractant protein
(MCP)-1 and fractalkine [1–5]. A range of experimental studies
have also suggested a pathogenic role for several of these
inflammatory mediators in the development and progression of
HF [4,6–8]. However, the role of inflammation in HF remains
incompletely understood. Identification of the most important
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mediators of the inflammatory pathways involved in the
pathogenesis of HF and their mechanism of action are issues that
need to be further clarified.
While most chemokines have been linked to inflammatory
processes in peripheral tissue, the homeostatic chemokines (i.e.,
CCL19, CCL21, and CXCL13) and their corresponding recep-
tors (i.e., CCR7 for [CCL19 and CCL21] and CXCR5 for
[CXCL13]) have been associated with development and mainte-
nance of secondary lymphoid organs [9–12], as well as the entry
of lymphocytes and dendritic cells to secondary lymphoid tissue
[13–15]. Recently, however, reports have pointed to a broader
role for these homeostatic chemokines, including modulation of
inflammatory and anti-inflammatory responses in lymphoid and
non-lymphoid tissue. Thus, while CXCL13 was known to dictate
homing and motility of B cells in lymphoid tissue, more recent
studies suggest that CXCL13 is involved in the formation of
ectopic lymphoid tissue in chronic inflammation [16,17]. This
chemokine has also been linked to T cell [9,18,19] and monocyte
activation [20] and apoptosis [21]. In line with its newly dis-
covered role in the immune system, CXCL13 has been suggested
to be involved in the pathogenesis of rheumatoid arthritis [22],
Sjo¨gren syndrome [23–25], inflammatory bowel disease [26], and
multiple sclerosis [27]. CXCR5 is a G protein-coupled seven
transmembrane receptor and belongs to the CXC chemokine
receptor family [28]. Recently, CXCR5 has been found to be
involved in remodeling of extracellular matrix (ECM) in various
types of cancer, including colon [29] and prostate cancer [30].
However, the potential role for CXCL13 and CXCR5 in the
pathogenesis of myocardial remodeling has not been studied.
Based on their potential role in inflammation and matrix
remodeling, we hypothesized that CXCL13 and its receptor
CXCR5 are involved in cardiac remodeling and development of
HF. We examined this hypothesis by studying the cardiac
morphology, function and molecular alterations in CXCR5
deficient (CXCR52/2) mice exposed to left ventricular (LV)
pressure overload induced by aortic banding (AB).
Results
Expression of CXCR5 and CXCL13 in murine hearts
We first examined if the CXCL13/CXCR5 dyad was regulated
during AB in mice. Both CXCL13 and CXCR5 were expressed
within the murine heart, and as shown in Fig. 1A and B, we found
significantly enhanced myocardial expression of CXCR5, but not
of CXCL13, in mice that underwent AB as compared with sham
operated mice. Within the myocardium, we found mRNA
expression of CXCL13 and CXCR5 in cardiomyocytes, fibro-
blasts and endothelial cells with the highest expression of both
CXCR5 and CXCL13 in myocardial fibroblasts (Fig. 2A, B).
Survival during LV pressure overload
As depicted in Kaplan-Meier survival curves (Fig. 3), CXCR52/2
mice exhibited significantly higher mortality rates than WT mice
during an 80-day follow-up after AB induction. The differences in
mortality emerged after 40 days of AB.
Severe LV dilatation in CXCR52/2 mice following
pressure overload
To investigate a potential role for CXCR5 in cardiac
remodeling and development of HF, we evaluated cardiac
morphology and function in WT and CXCR52/2 mice. Two-
dimensional and M-mode echocardiography performed in non-
operated WT (n= 6) and CXCR52/2 (n = 6) mice showed no
significant differences in LV function or dimensions (Table S1).
Twenty-one days after AB, echocardiographic assessment showed
comparable increases in flow velocities across the banded region of
the aorta in the WT and CXCR52/2 groups. However, LV
fractional shortening was reduced by 65% in CXCR52/2 mice,
but only by 13% in WT (Table S1). The mean LV diastolic
dimension was significantly larger and the LV posterior wall
thickness was significantly lower in CXCR52/2 mice compared to
WT mice at the same time point (Fig. 4A, B).
CXCR52/2 mice show increased expression of
hypertrophy maker genes in response to pressure
overload
Despite similar increases in heart weight to tibial length (HW/
TL) ratio in both genotypes after AB, CXCR52/2 mice exhibited
a more marked increase in expression of ANP (3.3-fold increase),
BNP (2.3-fold increase) and b-MHC (2.5-fold increase) than
WT (Fig. S1A–C). The marked increase in ANP and BNP in
CXCR52/2 mice following AB might suggest increased myocar-
dial wall stress in these mice.
CXCR52/2 mice exhibit major alterations in ECM in
response to pressure overload
Since alterations in extracellular matrix (ECM) might be
responsible for LV dilatation, we examined the quality and
composition of the ECM following AB. CXCR52/2 mice
exhibited increased myocardial collagen content following AB as
compared with WT mice, as illustrated by both Masson trichrome
staining (Fig. 5A) and hydroxyproline measurement by HPLC
(Fig. 5B). This increase in collagen content in CXCR52/2 mice
Figure 1. Myocardial gene expression of CXCL13 and CXCR5 in mice. Myocardial gene expression of (A) CXCL13 and (B) CXCR5 in wild type
(WT) Sham (n= 7) and WT aorta banded (AB) (n = 14) group. The results are mean 6 SEM. **p,0.01 vs. Sham group.
doi:10.1371/journal.pone.0018668.g001
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was accompanied by a significant increase in total matrix
metalloproteinase (MMP) activity (Fig. 5C) and gelatinolytic
activity (Fig. 5D, E). This combination of increased collagen
content and increased MMP activity suggest enhanced matrix
remodeling in CXCR5 deficient mice following AB.
Microarray analysis identified altered expression of genes
encoding non-collagen ECM proteins
In addition to collagen, the quantity and quality of other ECM
constituents also importantly influence cardiac function [31]. We
therefore performed microarray analysis (Affymetrix) of the
myocardium from WT and CXCR52/2 mice 3 weeks after AB.
The seeded Bayesian network method [32] was used to explore
interactions between differentially expressed genes. This analysis
identified a cluster of genes encoding ECM proteins. Interestingly,
this cluster contained fibromodulin which belongs to a family of
small leucine-rich repeat proteoglycans (SLRPs), which are known
to influence ECM assembly [33]. Microarray data are accessible
through GEO Series accession number GSE22295 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22295).
Protein levels of SLRPs following AB in CXCR52/2 and WT
mice
To further examine the regulation of SLRPs following AB, we
measured protein levels of fibromodulin and other members in the
SLRP family, including decorin, lumican and biglycan. With the
exception of biglycan, all of these SLRPs were differently regulated
in CXCR5 2/2 mice compared to WT mice following AB (Fig. 6).
While decorin and lumican markedly increased during AB in WT
mice, this was not observed in CXCR52/2 mice (Fig. 6A, B).
Moreover, while fibromodulin decreased following AB in WT and
CXCR5 2/2 mice, the decrease was significantly more pro-
nounced in the CXCR52/2 mice (Fig. 6C).
Electron microscopic analysis revealed loosely packed
ECM in CXCR52/2 mice following AB
SLRPs are capable of binding to different types of collagen
[34,35], thereby regulating fibril assembly and organization,
degradation, and quantitative and functional aspects of the
collagen network [33]. To further elucidate the effect of decreased
levels of SLRPs during pressure overload, LV tissue sections were
examined by electron microscopic analysis in WT and CXCR5-
deficient mice. As shown in Fig. 6D and E, a considerable increase
in the extracellular space was observed in LVs from CXCR52/2
as compared to WT mice. In addition, banded WT mice exhibited
densely packed collagen fibers of variable thickness and orientation
as well as proteoglycan particles associated with fine filaments
(Fig. 6F). In contrast, the ECM in CXCR52/2 mice exhibited
large areas with a coarse network of individual collagen fibrils, and
finer networks of proteoglycans with associated filaments (Fig. 6G),
suggesting deranged ECM.
No difference in apoptosis and leukocyte infiltration
between CXCR52/2 and WT mice after pressure overload
CXCL13 has been suggested to exhibit anti-apoptotic proper-
ties [36,37]. However, analysis of cardiac apoptosis by in situ
TUNEL staining revealed that, after either sham-operation or AB,
the number of apoptotic cells was similar in WT and CXCR5-
deficient mice (Fig. S2). Moreover, although CXCL13 is known to
influence lymphocyte trafficking [38,39], we found no significant
Figure 2. Gene expression of CXCL13 and CXCR5 in myocardial cells in mice. Gene expression of (A) CXCL13 and (B) CXCR5 in
cardiomyocytes, fibroblasts and endothelial cells from wild type mice (n = 3). mRNA levels were assesssed by quantitaive real time PCR. AU=Arbitrary
unit. The results are mean 6 SEM. * p,0.05, **p,0.01, ***p,0.001 vs. cardiomyocytes. {{p ,0.01 vs. fibroblasts.
doi:10.1371/journal.pone.0018668.g002
Figure 3. Kaplan-Meier survival curves of wild type (WT)
(n=20) and CXCR52/2 mice (n=20) after aortic banding (AB).
Echocardiographic assessment showed comparable increases in flow
velocities across the banded region of the aorta in WT and CXCR52/2
twenty-one days after primary surgery. Differences in survival between
WT and CXCR52/2 mice were tested with the log-rank test. *p,0.05 vs.
WT.
doi:10.1371/journal.pone.0018668.g003
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difference in infiltration of CD3+ or CD45+ cells between
CXCR52/2 and WT mice after either sham operation or AB
(Fig. S3A and B).
CXCL13 stimulates expression of SLRPs
The changes in ECM in CXCR52/2 mice following AB,
consisting of enhanced MMP activity and decreased expression of
several SLRPs, could potentially reflect direct effects of CXCL13
on myocardial fibroblasts. In fact, both CXCL13 and CXCR5
were strongly expressed within myocardial fibroblasts, and
CXCR5 showed enhanced myocardial expression during AB in
WT mice (Fig. 1). In addition, fibroblasts are important producers
of ECM proteins, including SLRPs. Stimulation of cardiac
neonatal rat fibroblasts with CXCL13 did indeed enhance the
expression of fibromodulin, biglycan and lumican, and in
particular of decorin, and at the same time down-regulated total
MMP activity (Fig. 7A, B).
CXCL13-CXCR5 mediate their effects on matrix
modulation via ERK1/2 signaling
We next examined alterations in the ERK1/2 pathway in
CXCR52/2 following AB, as this pathway is of importance in
cardiac remodeling and since CXCL13 signaling through CXCR5
is known to activate the MAPK pathway via ERK 1/2 [40,41]. As
shown in Fig. 7C and D, LV from CXCR52/2 mice showed
decreased levels of phosphorylated ERK1/2 as compared with
WT mice. In cardiac fibroblasts, blocking the ERK1/2 pathway
by UO126, a highly selective inhibitor of MEK 1 and 2,
significantly attenuated up-regulation of fibromodulin following
CXCL13 treatment (Fig. 7E).
Expression of CXCR5 and SLRPs in patients with HF
Assessments of CXCR5 mRNA levels in myocardial tissue from
9 HF patients (all with advanced HF, NYHA class IV) and 5
controls (non-failing hearts) showed that HF patients had markedly
enhanced gene expression of CXCR5 (84% increase, p,0.005).
As shown in Fig. 7, the 9 HF patients also had significantly
enhanced gene expression of biglycan, lumican and fibromodulin.
When the HF patients were treated with continuous-flow LV assist
device (LVAD) for 861.7 months, improvement in hemodynamic
parameters (LV end diastolic volume decreased from 294.9 mL to
237.8 mL, LV diastolic diameter from 7.6 cm to 6.8 cm, and LV
end systolic volume from 244.8 mL to 183.4 mL, reflected in an
increase in LVEF from 18.2 to 29.6%, p,0.05 for all) was
accompanied by a marked decrease in mRNA levels of CXCR5 as
well as biglycan and fibromodulin, although the decrease in
fibromodulin did not reach statistical significance (Fig. 8).
Discussion
Despite observations of enhanced levels of chemokines and their
corresponding receptors in human HF [5,42,43], the role of
chemokines in maintaining cardiac structure and function has
never been established. The present work clearly demonstrates that
the chemokine CXCL13 and its receptor, CXCR5, are critically
involved in cardiac remodeling. The key results of this study were
increased mortality and severe LV dilatation in CXCR5-deficient
mice in response to pressure overload, potentially resulting from
impaired quality of ECM. These ECM alterations derived, at least
partly from decreased SLRP levels and enhanced MMP activity
within the myocardium. Our in vitro findings showed that CXCL13
can promote SLRP expression and attenuate MMP activity in
myocardial fibroblasts. Therefore, the opposite pattern seen in
CXCR5-deficient mice could reflect the inability of their
myocardial fibroblasts to respond to CXCL13. These data indicate
that the CXCL13/CXCR5 interaction is involved in myocardial
remodeling following pressure overload, possibly by regulating
proteoglycans crucial for the quality of myocardial ECM. Our
findings of a strong expression of CXCL13 and CXCR5 in
fibroblasts within murine hearts and enhanced myocardial
expression of CXCR5 during AB further support such a notion.
The possible role of chemokines in the pathogenesis of HF has,
at least in part, been attributed to the ability of these molecules to
promote leukocyte infiltration in failing myocardium. However, in
the present study we did not detect altered infiltration of CD3+
and CD45+ cells in CXCR52/2 mice compared to the WT mice
following AB. Previously, various chemokines (e.g., CXCL16,
MCP-1 and CX3CL1) have been shown to promote direct effects
on myocardial fibroblasts and cardiomyocytes in vitro [5,43–45].
Also, the lack of CXCR4 has been associated with severe
myocardial developmental defects (i.e., ventricular septum defects)
[46]. In contrast to CXCR4, CXCR5 deficient mice are viable
and display normal morphology and function of the adult heart.
However, our present data showing a markedly dilating
myocardial phenotype in CXCR52/2 mice exposed to pressure
Figure 4. Left ventricular (LV) dilatation in CXCR52/2mice 3 weeks following aortic banding (AB). LV inner diameter (A) and thickness of
the posterior wall (B) were measured in the wild type (WT) Sham (n= 6), CXCR52/2 Sham (n= 6), WT AB (n = 6), and CXCR52/2 AB (n = 6) groups. The
results are mean 6 SEM. *p,0.05 and ***p,0.001 vs. Sham groups; {{p,0.01 and {{{p,0.001 vs. WT AB group.
doi:10.1371/journal.pone.0018668.g004
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overload, without any significant changes in myocardial leukocyte
infiltration, may suggest a direct involvement of CXCL13/
CXCR5 activation in myocardial remodeling. The ability of
CXCL13 to attenuate MMP activity and increase SLRP
expression in myocardial fibroblasts as well as the up-regulation
of CXCR5 during AB in WT mice further supports such a notion.
Figure 5. Extracellular matrix remodeling in wild type (WT) and CXCR52/2 mice following aortic banding (AB). Collagen content in
myocardium examined with (A) Masson trichrome staining in representative sections from AB WT and CXCR52/2 mice and (B) by hydroxyproline
measurement in WT Sham (n = 13), CXCR52/2 Sham (n = 12), WT AB (n = 13) and CXCR52/2 AB (n = 14) groups. (C) Total MMP activity in percentage of
the WT Sham group (n = 11) measured in the CXCR52/2 Sham (n= 13), WT AB (n = 9), and CXCR52/2 AB groups (n = 9). (D) Gelatinolytic activity of
MMP-2 relative to the WT Sham group (n = 5) measured in the CXCR52/2 Sham (n= 5), WT AB (n = 5), and CXCR52/2 AB groups (n = 5) and of (E) MMP-
9 relative to the WT Sham group (n = 6) measured in the CXCR52/2 Sham (n= 6), WT AB (n = 8), and CXCR52/2 AB groups (n = 9). The results are mean
6 SEM. *p,0.05, **p,0.01 and ***p,0.001 vs. Sham groups; {p,0.05 and {{p,0.01 vs. WT AB groups.
doi:10.1371/journal.pone.0018668.g005
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Collagen synthesis, fibrillogenesis, and matrix degradation must
be finely tuned, as an imbalance in these processes might result in
cardiac dilatation, cardiac hypertrophy and fibrosis. Although we
observed increased total collagen content in CXCR52/2 mice,
these mice were also characterized by massively disturbed
structural frameworks after AB compared to WT. Our molecular
analysis suggested that this distorted ECM structure derives from a
failure in the regulation of SLRPs in pressure overloaded CXCR5-
deficient mice. SLRPs are known to bind to collagens, and in so
doing, regulate the self-assembly process of pro-collagen into fibrils
[33–35]. This assembly is necessary for covalent cross-linking
which is required for reinforcement of the collagen fibrils. SLRPs
have been shown to be up-regulated in the infarcted area in rats
and mice following myocardial infarction (MI) [47,48]. Studies in
SLRP deficient mice have shown abnormal fibril organization and
loose fibril packing in the MI scar [49,50]. In the current study we
show an attenuated up-regulation (i.e., decorin and lumican) and a
more pronounced decrease (i.e., fibromodulin) in SLRP expression
following AB in CXCR5 deficient mice as compared with WT
mice. Interestingly, enhanced MMP activity has been found to
impair SLRP function [44], and we suggest that the combination
of decreased SLRP expression and increased MMP activity could
be of major importance for the premature LV dilatation and HF
in CXCR52/2 mice following AB.
Our in vitro data suggest that CXCL13 via activation of CXCR5
on myocardial fibroblasts induces the expression of SLRPs
through the ERK1/2 pathway. This mechanism appears to be
absent in fibroblasts from CXCR52/2 mice. ERK is one of the
key protein kinases that regulate growth and proliferation of
cardiac fibroblasts [40]. In line with a crucial role of CXCL13/
CXCR5-mediated ERK1/2 activation for cardiac remodeling in
response to pressure overload, ERK1/2 phosphorylation was
substantially lower in CXCR52/2 mice compared to WT after
AB. These findings further support previous reports of a central
role of the ERK pathway for myocardial remodeling [51,52]. In
this regard, the present study adds a novel component to this
pathway by linking CXCR5-mediated effects to SLRPs and
subsequent ECM remodeling.
Our studies in patients with advanced HF suggest that our
findings in experimental HF may have relevance to clinical HF.
We showed enhanced myocardial expression of CXCR5 and
certain SLRPs (i.e., biglycan, lumican and fibromodulin) in the
failing myocardium, and notably, biglycan and lumican were
down-regulated following the clinical and hemodynamic improve-
ment during treatment with LV assist device. Based on our
experimental data, it is tempting to speculate that CXCR5
activation promotes protective responses in ECM in failing
myocardium involving enhanced expression of SLRPs. As
Figure 6. Protein levels of small leucine-rich repeat proteoglycans (SLRPs) and transmission electron microscopic analysis in wild
type (WT) and CXCR52/2 mice following aortic banding (AB). Protein levels of (A) decorin and (B) lumican in (WT) Sham (n= 7), CXCR52/2
Sham (n= 5), WT AB (n = 6), and CXCR52/2 AB (n = 5), and (C) fibromodulin in WT Sham (n = 13), CXCR52/2 Sham (n= 12), WT AB (n = 12), and
CXCR52/2 AB (n = 11) groups as assessed by western blotting. The upper panels show representative blots from two mice in each group.
1 Glycosylated forms of decorin and lumican, respectively. The results are mean 6 SEM. *p,0.05, **p,0.001 and ***p,0.001 vs. Sham groups;
{p,0.05 and {{p,0.01 vs. WT AB group. The lower panels show representative transmission electron micrographs of the LV free wall at6440 and
623000 magnification in WT (D and F) and CXCR52/2 (E and G) AB mice.
doi:10.1371/journal.pone.0018668.g006
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myocardial function improves, this response is attenuated. At
present, however, the stimuli for enhanced myocardial CXCR5
expression in HF and the interpretation of our human data will
require further investigation.
In conclusion, we have found that CXCR5 plays an important
role in cardiac remodeling during pressure-overload. Loss of
CXCR5 in this situation adversely affects matrix remodeling and
causes LV dilatation, possibly through altered regulation of
proteoglycans crucial for the quality of myocardial ECM (i.e.,
SLRPs) as well as through enhanced MMP activity. These changes
could, at least in part, be attributed to loss of CXCL13 mediated
effects on myocardial fibroblasts in CXCR5 deficient mice. The
Figure 7. Effects of CXCL13 on gene expression of small leucine-rich repeat proteoglycans (SLRPs), total MMP activity and the
intracellular signalling pathway ERK 1/2 in neonatale rat fibroblasts (FB). The effect of CXCL13 (200 ng/ml) stimulation on gene expression
of (A) decorin, biglycan, lumican and fibromodulin (n = 4) in myocardial FB after 20 hours of stimulation in relation to GAPDH and (B) total MMP
activity in cell-free supernatant (n = 7) after 20 hours of stimulation. The ratio of phosphorylated ERK 1/2 (p-ERK 1/2) to total ERK 1/2 assessed by (C)
western blotting in WT Sham (n= 13), CXCR52/2 Sham (n = 12), WT AB (n = 11), and CXCR52/2 AB (n = 10) groups, and by (D) BioPlex in WT Sham
(n = 6), CXCR52/2 Sham (n = 5), WT AB (n = 7), and CXCR52/2 AB (n = 6) groups. (E) The effect of blocking ERK 1/2 activation with UO126 (10 mM) on
the CXCL13-mediated induction of fibromodulin gene expression in myocardial FB (n = 4). The results are mean 6 SEM. *p,0.05 and **p,0.01 vs.
unstimulated FB or CXCR52/2 Sham; {p,0.05 vs. WT AB group, {p,0.05 vs. CXCL13 stimulated FB without inhibitor (UO126).
doi:10.1371/journal.pone.0018668.g007
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identification of molecular and structural changes causing LV
dilatation during pressure overload is of major importance for the
development of new treatment strategies in HF related to
hypertension and aortic stenosis. Future studies should examine
how the CXCL13/CXCR5 dyad could be utilized therapeutically
in clinical HF.
Materials and Methods
Ethics
All animal experiments were approved by the Norwegian
Animal Research Committee (ID 1902) and conform to the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–23, revised
1996). The part of the study that involved humans was approved
by the local ethics committee (REK Helse Sør-Øst) and conducted
according to the ethical guidelines outlined in the Declaration of
Helsinki for use of human tissue and subjects. Informed written
consent was obtained from all subjects. The authors had full access
to the data and take responsibility for its integrity. All authors have
read and agree to the manuscript as written.
Data analysis
All data are expressed as group means 6 SEM unless indicated
otherwise. For comparisons of 2 groups, the Mann-Whitney U test
was employed. The Wilcoxon test was employed when analysing
the effect of LVAD treatment. Differences between the WT Sham,
WT AB, CXCR52/2 Sham, and CXCR52/2 AB groups were
determined by one-way ANOVA with post-hoc Tukey test.
Differences in survival between wild type and CXCR52/2 mice
in Fig. 3 were compared using Kaplan- Meier survival curves and
tested with the log-rank test. All tests were employed using a 5%
significance level.
Animals and AB protocol
Mice were housed in M2 or M3 cages with Bee Kay bedding
(Scanbur BK, Nittedal, Norway) in 55% humidity on a 12 h light/
dark cycle. Food pellets (RM1, 801151, Scanbur BK) and water
were freely available. All mice utilized in this study were male and
had a weight 20–30 g. WT C57BL/6 mice were obtained from
Taconic (Skensved, Denmark). The generation of CXCR52/2
mice (C57BL/6 background, now accessible at the Jackson
Laboratory, stock number 006659, strain name B6.129S2 (Cg)-
Cxcr5tm1Lipp/J has been described previously [14]. Briefly, gene
targeting was performed in 129S2/SvPas-derived D3 embryonic
stem cells, replacing the coding region of the CXCR5 gene with a
neomycin resistance gene. Mutant mice were backcrossed to
C57BL/6 mice for 8 generations. AB was induced in C57BL/6
and CXCR52/2 mice as previously described [53]. Briefly, after
being anesthetized with 5% isoflurane and ,98% oxygen in a gas
chamber, the animals where endotracheal intubated and the
cannula was connected to a volume cycled rodent ventilator
(Harvard Apparatus) on supplement of a mixture of ,1.75%
isoflurane and ,98% oxygen. A thoracotomy was performed in
the second intercostal space on the left side, and the aortic
constriction was created by placing a ligature securely around the
ascending aorta and a 26-gauge needle and then removing the
needle. Sham operated animals underwent the same procedure
except for aortic constriction. The animals were extubated after
getting a dose of analgesic (buprenorphine, 0.1 mg/kg) subcuta-
Figure 8. Gene expression of CXCR5, biglycan, lumican and fibromodulin in patients with heart failure (HF) (n =9) and controls
(n =5) as assesssed by quantitaive real time PCR. In the HF patients, the mRNA levels were measured before and after treatment with
continuous-flow left ventricular assist device (LVAD).
doi:10.1371/journal.pone.0018668.g008
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neously and allowed to recover. Doppler echocardiography was
performed 21 days after primary surgery under general anaesthe-
sia with isoflurane as described above. This time point was selected
since previous studies in our laboratory have shown marked
hypertrophy in WT mice at this stage. AB mice in both groups
with a flow velocity across the aortic banding site greater than
3.5 m/s were included in the study. The same mice anesthetized
with isoflurane were euthanized by dislocation of the neck, and the
hearts and lungs were removed and blotted dry. The right
ventricle and atria were removed. The LV, right ventricular free
wall and lungs were weighed and normalized to tibial length.
Doppler Echocardiography
Mice were examined while sedated in the supine position with
the chest closed, as previously described [54]. Echocardiography
was performed using a i13L 13 MHz linear array transducer (GE
Healthcare Technologies, Oslo, Norway) and data were analyzed
with EchoPac PC software (GE Healthcare Technologies, Oslo,
Norway) as described [55]. The data were recorded and analyzed
by a cardiologist (IS), blinded for the genotype.
Isolation of adult myocardial murine cardiomyocytes,
fibroblasts and endothelial cells
Mouse cardiomyocytes were isolated as previously described
[56]. Endothelial cells were enriched from the non-cardiomyocyte
fraction by labeling the cells with a rat anti-mouse CD31 antibody
(eBioscience, San Diego, CA) and subsequent extraction using an
anti-rat secondary antibody coupled to magnetic beads (Miltenyi
Biotec, Auburn, CA) and further column purifications according
to the protocols provided by the manufacturer (http://www.
miltenyibiotec.com). The cell fraction remaining after extraction of
cardiomyocytes and endothelial cells contains predominantly
fibroblasts.
RNA isolation
Total RNA was isolated from the LV in WT and CXCR52/2
mice (SV total RNA isolation system, Promega, Inc., Madison,
WI), mouse and neonatal rat cardiomyocytes and fibroblasts, and
mouse endothelial cells (RNeasy mini kit, Qiagen, Valencia, CA)
as previously described [5].
Quantitative real-time PCR (qRT-PCR)
Reverse transcription reactions were performed with iScript
Select cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules,
CA). Pre-designed TaqMan assays (Applied Biosystems,
Foster City, CA) were used to determine gene expression
of CXCL13(Mm00444534_m1), CXCR5 (Mm00432086_m1),
ANP (Mm01255748_g1), BNP (Mm00435304_g1), b-MHC
(Mm01319006_g1), biglycan (Rn00567229_m1), fibromodlin
(Rn00589918_m1), lumican (Rn00579127_m1) and decorin
(Rn01503161_m1). The results were detected on an ABI PRISM
7900 Sequence Detection System (Applied Biosystems) as
described previously [5]. In the human studies, quantification of
gene expression was performed using the ABI Prism 7500 (Applied
Biosystems), Power SYBR Green Master Mix (Applied Biosys-
tems), and sequence-specific PCR primers were designed using the
Primer Express software, version 3.0 (Applied Biosystems). List of
the real-time PCR assays used in the human study is shown in
Table S2.
Perfusion fixation and histology
After the hearts were excised and rinsed in cold NaCl solution,
the aorta was cannulated, and the hearts were mounted on a
Langendorff setup, and retrogradely perfused with warm (37uC)
oxygenated Thyrodes solution (5 mM Hepes, pH 7.4, 140 mM
NaCl, 5.4 mM KCl, 0.4 MgH2PO4, 0.5 MgCL2) with 1.8 mM
Ca2+. Hearts were stopped in diastole by aortic perfusion of
Thyrodes solution with high KCl (10.8 mM) for 3 min and fixated
for 10 min by perfusion of 4% phosphate-buffered formalin. After
the cannulas were removed, fixation by immersion continued for
2 h. Each heart was transected at the midventricular level, and
both halves were routinely processed and embedded in paraffin.
Paired 3.5 mm sections were prepared, mounted on glass slides,
and stained with hematoxylin and eosin and Masson tricrome
stain.
Hydroxyproline analysis
Quantitative analysis of tissue levels of hydroxyproline was
performed by HPLC using the AccQ-Fluor reagent kit (Waters
Corporation, Milford, MA) essentially as previously described
[57]. Briefly, cardiac tissue samples (5 mg dry weight) were
hydrolyzed in 6 M HCl for 16 h at 110uC and subsequently dried
under vacuum and redissolved in the AccQ-Fluor borate buffer.
Derivatization was initiated by addition of the AccQ-Fluor reagent
at 55uC and terminated after 10 min. The samples were finally
subjected to HPLC-chromatography using a 2063.9 mm Sentry
Guard column (Nova-Pak C18 bonded silica) connected to a
15063.9 mm AccQ-Tag reversed-phase column (both from
Waters) according to the manufacturer’s instructions. Derivatized
hydroxyproline was detected by fluorescence signal following
excitation at 250 nm and recording of emission at 395 nm.
Elution of hydroxyproline from myocardial tissue samples was
verified and quantified by co-elution with known amounts of
derivatized hydroxyproline standards (Fluka, Buchs SG, Switzer-
land). The relation of myocardial hydroxyproline contents to
myocardial collagen has previously been reported [58].
Measurements of total MMP activity and gelatinolytic
activity
Total MMP activity in the LV was measured by a fluorogenic
peptide substrate (R&D Systems) used to assess broad-range MMP
activity (MMP-1, -2, -7, -8, -9, -12 and -13 can cleave the peptide).
Gelatinolytic activity was assessed by gelatine zymography. Briefly,
the MMP substrate was diluted in TCN buffer (50 mM Tris HCl,
150 mM NaCl, 10 mM CaCl2; pH 7.5) and added to the
supernatants before incubation at 37uC. After 120 min the total
MMP activity was determined on a fluorimeter (FLX 800Microplate
Fluorescence Reader, Bio-Tek Instruments, Winooski, VT).
Gene expression profiling and microarray data analysis
Total RNA was isolated from the LV in Sham (n= 3) and AB
(n= 4) WT and CXCR5-/- mice as described previously [5].
Preparation of cRNA and the subsequent steps leading to
hybridization of Affymetrix GeneChipH mouse ST 1.0 arrays
(Affymetrix, Santa Clara, CA), washing, and scanning were
performed according to standard protocols (Affymetrix). Micro-
array preprocessing was done using robust multi-array average
[59]. Differentially expressed genes were found using significance
analysis of microarrays [60]. The seeded Bayesian network
method [32] was used to explore interactions between differen-
tially expressed genes. This method finds interactions in the
expression data using literature co-citations, databases of protein-
protein interactions, as well as co-regulations in the expression
data. We constructed two networks; one for the wild type situation,
using the 60 most differentially expressed genes between AB WT
and SHAMWT, and similarly one for the KO situation, using the
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60 most differentially expressed between CXCR52/2 AB and
Sham AB. The set of 60 genes were based on a ranking according
to fold change (AB vs. Sham) using a subset of the genes for which
false discovery rate was less than 0.05. All data is MIAME com-
pliant and the following link has been created to allow review of
the data in Gene Expression Omnibus (record GSE22295): http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xdivnmkmeyeiifg&
acc=GSE22295
Western blotting
Western blotting was performed as previously described [61]
with minor modifications. Snap frozen left ventricles from WT and
CXCR52/2 mice were homogenized in cell lysis buffer and equal
amounts of protein being separated from each sample by SDS-
PAGE (10%) before transferred to polyvinylidene fluoride (PVDF)
membranes. Non-specific bindings to the membrane was blocked
with 5% BSA for 1 h at room temperature, followed by incubation
with anti-fibromodulin (SC-33772; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), anti-decorin (AF1060; R&D Systems,
Minneapolis, MN), anti-biglycan (AF2667; R&D) or anti-lumican
(AF2745; R&D) overnight at 4uC. The membranes were washed
in TBS-T and followed by species-specific horseradish peroxidase-
coupled secondary antibodies in 5% BSA added for 1 h. After
washing, the immune complexes were visualized by ECL (GE
Healthcare, Buckinghamshire, UK) and the membranes were
exposed to x-ray film (HyperfilmTM ECL, GE healthcare) and
developed. Immunoblots were stripped and re-probed with anti-
GAPDH (C20357; R&D) for normalization. Filters with LV lysate
were also probed with antibody against P-ERK1/2 (Phospho-p44/
42 MAP kinase (Thr 202/Tyr 204), Cell Signaling Technology,
Danvers, MA) or p44/42 MAP kinase (Cell Signaling Technology)
followed by species-specific horseradish peroxidase-coupled sec-
ondary antibodies (Cell Signaling). The immune complexes were
visualized with the use of Supersignal West Pico (Pierce, Rockford,
IL) and exposed films were detected by using Kodak 440 CF
imaging station (Boston, MA). The software Total Laboratory
v.1*10 (Phoretix, Newcastle, UK) was used for quantification.
Transmission electron microscopy
For transmission electron microscopy, hearts (n = 2) from each
group were perfused with 2.0% glutaraldehyde buffered in 0.2 M
cacodylate at pH 7.4 for 15 min. Small blocks (about 3 mm3 in
size) of the LV and septum were taken. The tissues were fixated in
cacodylate buffer for 2 h and washed in the same buffer 3 times.
The blocks of tissue were then transferred to a 1% OsO4 solution
for 10 min on ice. After washing in cacodylate, dehydration was
carried out rapidly in graded ethanol series, followed by
embedding in Epon. Sections were cut at a thickness of 60–
100 nm and collected on 200 mesh grids, and stained with uranyl
acetat for 7 minutes and lead for 3 minutes. The sections were
examined and photographed in a Tecnai G2 spirit BioTWIN
120 kV, LaB6, Transmission Electron Microscope with 4k Eagle
camera from FEI Company. We obtained micrographs of the LV
septum and the free wall at different magnifications.
TUNEL Staining
TUNEL staining was performed on paraffin-embedded sections
using the In Situ Cell Death Detection kit (Roche Diagnostics) as
described [62]. Briefly, paraffin-embedded (6 mm) sections of
mouse hearts were deparaffinized in xylene, rehydrated, and
treated with 0.5% Triton X-100 in 0.1% Na-citrate for 30 min.
After several washes with PBS, the sections were permeabilized
with proteinase K (20 mg/ml in TE, pH 8.0) for 30 min at 37uC.
Subsequently, the sections were rinsed with PBS, and the area
around the sample was dried. TUNEL reaction mixture (50 ml)
containing terminal deoxynucleotidyl transferase was applied and
tissue sections were incubated in a dark, humidified chamber for
1 h at 37uC. After several washes with PBS the tissue sections were
analyzed with a fluorescence microscope (515–565 nm). A
quantitative analysis (number of apoptotic cells/total number of
cells counted) was performed by counting cells in a randomly
selected area of each tissue sample.
Immunohistochemistry
Paired 3.5 mm sections were immunostained using affinity-
purified rabbit polyclonal CD3 antibody (Abcam, Cambridge,
U.K.), dilution 1:400, and anti-mouse/human CD45R (eBioscience,
San Diego, CA), dilution 1:4500. The immune reaction was
visualized using horseradish peroxidase in a Dako Autostainer plus
(Dako, Glostrup, Denmark). We obtained 32 digital images of evenly
distributed microscopic high power fields (6400) from the left
ventricular free wall and ventricular septum of six heart sections in
each group. The sections were from no less than three hearts in each
group. The 32 images from each heart were studied by two
investigators (AW and HMR), blinded for mouse identity, counting
the total number of CD3 and CD45R positive lymphocytes.
Isolation and stimulation of neonatal myocardial rat
fibroblasts
Primary neonatal fibroblasts were isolated from 1–3 day old
Wistar rats (Taconic, Skensved, Denmark). Briefly, fibroblasts
were separated by Percoll density gradient and transferred to
plating medium and maintained in culture for up to 96 hours. The
fibroblasts were stimulated with human recombinant CXCL13,
200 ng/ml (R&D Systems, Minneapolis, MN), with or without the
ERK1/2 inhibitor (10 mM final concentration UO126 (MEK
inhibitor, Promega, WI)), for 3 and 20 hours before storing cell
pellet (mRNA analyses) and cell-free supernatant (MMP activity)
at 280uC until further analyses. Un-stimulated (control) cells were
also given vehicle. The toxicity in cell cultures was examined
routinely for lactate dehydrogenase leakage using a cytotoxicity
detection kit (Roche Applied Science, Mannheim, Germany).
P-ERK1/2 (Phospho-p44/42 MAP kinase) and ERK1/2
(p44/42 MAP kinase) detection
Phospho-p44/42 MAP kinase and p44/42 MAP kinase levels in
left ventricle lysate were measured by multiplex suspension
array technology using the BioPlex (Bio-Rad, Hercules, CA).
Phospho-p44/42 MAP kinase and p44/42 MAP kinase multi-
plexable beads were purchased from R&D Systems. The quan-
tification was accomplished by using the BioPlex Manager
Software (Bio-Rad).
Tissue sampling from human myocardium
In nine patients with advanced HF (NYHA class IV; 8 male, 1
female; age 2965 years), LV tissue was available at the time of
implantation and at the time of removal (heart transplantation) of
a continuous-flow LV assist device (LVAD; EntrAssist, Ventracor
Ltd, Chatswood, Australia). Average time on LVAD was 861.7
months. Control (non-failing) human LV tissue was obtained from
subjects whose hearts were rejected as cardiac donors for surgical
reasons (n = 5). The cause of death of donors was cerebrovascular
accident, and none had a history of heart disease. Myocardium
from these subjects was kept on ice for 1 to 4 hours before tissue
sampling was conducted. In both failing and non-failing
myocardium, LV tissue samples were snap-frozen in liquid
nitrogen, and stored at 280uC until use. None of patients (failing
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and non-failing myocardium) had significant concomitant disease
such as infection, malignancy, or autoimmune disorder.
Supporting Information
Figure S1 Altered expression of markers of cardiac wall
stress and remodeling. Relative gene expression of (A) atrial
natriuretic peptide (ANP), (B) brain natriuretic peptide (BNP) and
(C) b-myosin heavy chain (MHC) in wild type (WT) Sham (n= 6),
CXCR5-/- Sham (n= 6), WT aorta banded (AB) (n = 6), and
CXCR5-/- AB (n= 6) groups. The results are mean 6 SEM.
*p,0.05 and ***p,0.001 vs. Sham groups; {p,0.05 and
{{{p ,0.001 vs. WT AB group.
(TIF)
Figure S2 Fluorescent micrographs of sections of left
ventricular myocardium from wild type (WT) and
CXCR5-/- mice. The arrows indicate TUNEL-positive myocyte
nucleus.
(TIF)
Figure S3 CD45 and CD3 positive lymphocytes in the
left ventricular myocardium from wild type (WT) and
CXCR5-/- mice. Total number of CD45R (A) and CD3 (B)
postive lymphocytes was not significantly different between
CXCR5-/- and WT mice after sham operation or AB. (n = 6
heart sections in all groups). Cells counted from 32 digital, evenly
distributed images (x400) from each heart.The results are mean 6
SEM.
(TIF)
Table S1 Weights and echocardiographic measure-
ments. Values are means 6 SE. BW, body weight; TL, tibia
length; LVW, left ventricular weight; LW, lung weight; IVSd and
IVSs, interventricular septum thickness in diastole and in systole,
respectively; LVDd and LVDs, left ventricular diameter in diastole
and in systole, respectively; FS, fractional shortening in LVD;
LVPWd and LVPWs, posterior wall thickness in diastole and in
systole, respectively; LAD, left atrial diameter; HR, heart rate;
AVmax, peak aortic stenosis flow velocity; TVs, peak tissue
velocity in systole; TVd, peak tissue velocity in diastole. LVW/TL
and LW/TL are mg/mm. * p,0.05, ** p,0.01, *** p,0.001 vs.
Non-operated and Sham groups. {p,0.05, {{, p ,0.01,
{{{p,0.001 vs. WT AB group. {p,0.05 vs CXCR5-/- Non-
operated group. The results are mean 6 SEM.
(DOC)
Table S2 Characteristics of the real-time PCR assays
used in the human study. The table shows the sequence of
primers used in the real-time PCR assays. (+), forward primers;
(–), reverse primers; Acc.nr, GenBank accession number; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
(DOC)
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SUPPLEMENTARY INFORMATION 
 
Figure S1. Altered expression of markers of cardiac wall stress and remodeling. Relative gene 
expression of (A) atrial natriuretic peptide (ANP), (B) brain natriuretic peptide (BNP) and (C) β-
myosin heavy chain (MHC) in wild type (WT) Sham (n=6), CXCR5-/- Sham (n=6), WT aorta banded 
(AB) (n=6), and CXCR5-/- AB (n=6) groups. The results are mean ± SEM. *p<0.05 and ***p<0.001 
vs. Sham groups; †p<0.05 and †††p <0.001 vs. WT AB group.  
 
Figure S2. Fluorescent micrographs of sections of left ventricular myocardium from wild type (WT) 
and CXCR5-/- mice. The arrows indicate TUNEL-positive myocyte nucleus.  
 
Figure S3. Total number of CD45R (A) and CD3 (B) postive lymphocytes was not significantly 
different between CXCR5-/- and WT mice after sham operation or AB. (n=6 heart sections in all 
groups). Cells counted from 32 digital, evenly distributed images (x400) from each heart.The results 
are mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1.  Weights and echocardiographic measurements 
 
 
 
Table S1.  Values are means ± SE. BW, body weight; TL, tibia length; LVW, left ventricular weight; 
LW, lung weight; IVSd and IVSs, interventricular septum thickness in diastole and in systole, 
respectively; LVDd and LVDs, left ventricular diameter in diastole and in systole, respectively; FS, 
fractional shortening in LVD; LVPWd and LVPWs, posterior wall thickness in diastole and in systole, 
respectively; LAD, left atrial diameter; HR, heart rate; AVmax, peak aortic stenosis flow velocity; 
TVs, peak tissue velocity in systole; TVd, peak tissue velocity in diastole. LVW/TL and LW/TL are 
mg/mm. * p<0.05, ** p<0.01, *** p<0.001 vs. Non-operated and Sham groups. †p<0.05, ††, p <0.01, 
†††p<0.001 vs. WT AB group. ‡p<0.05 vs CXCR5-/- Non-operated group. The results are mean ± 
SEM. 
 
 WT CXCR5-/- WT Sham CXCR5-/- Sham WT AB CXCR5-/- AB 
n 6 6 7 7 6 8 
Weights       
BW (g) 26.2±0.8 25.3±0.7 27.9±0.9 25.8±0.9 27.8±1.0 26.4±0.6 
TL (mm) 18.2±0.1 17.3±0.3 18.0±0.1 17.6±0.1 18.3±0.1 17.3±0.4 
LVW/TL  5.4±0.2 5.2±0.3 5.5±0.2 5.3±0.3 8.6±0.5*** 8.6±0.3** 
LW/TL 8.9±0.2 9.0±0.5 8.7±0.2 9.1±0.5 17.6±2.5** 16.0±2.7* 
Echocardiography       
M-Mode       
IVSd (mm) 0.56±0.09 0.56±0.06 0.68±0.07 0.62±0.03 0.98±0.18** 0.67±0.12† 
IVSs (mm) 0.87±0.08 0.83±0.15 1.02±0.13 0.96±0.17 1.38±0.27*** 0.79±0.16††† 
LVIDd (mm) 4.50±0.37 4.28±0.17 4.43±0.30 4.59±0.32 4.31±0.29 5.40±0.59*† 
LVIDs (mm) 3.63±0.42 3.42±0.22 3.54±0.56 3.68±0.25 3.43±0.47 5.03±0.80**†† 
FS (%) 19.13±4.55 20.25±4.07 20.86±2.34 19.67±1.03 20.50±5.75 7.50±5.21*† 
LVPWd (mm) 0.63±0.09 0.61±0.06 0.67±0.15 0.60±0.11 1.10±0.22*** 0.68±0.14††† 
LVPWs (mm) 0.84±0.09 0.76±0.10 0.98±0.19 0.79±0.07 1.36±0.16*** 0.87±0.22††† 
LAD (mm) 1.59±0.2 1.78±0.14 1.73±0.14 1.71±0.09 2.58±0.55*** 3.17±0.41*** 
Doppler       
HR (BMP) 430.3±78.03 471.8±36.3 417.6±29.2 433.3±58.4 453.8±92.7 463.5±68.9 
       AVmax (m/s)     4.12±0.19 4.33±0.54 
       TVs (cm/s) 1.33±0.37 1.54±0.30 1.18±0.35 1.11±0.16‡ 0.77±0.28*** 0.66±0.31*** 
TVd (cm/s) 1.50±0.27 1.63±0.19 1.18±0.60 0.99±0.18 0.91±0.47 0.73±0.38** 
Table S2.  Real-time PCR assays in the human study 
 
 
Table S2. Characteristics of the real-time PCR assays used in the human study. The table shows 
the sequence of primers used in the real-time PCR assays. (+), forward primers; (–), reverse primers; 
Acc.nr, GenBank accession number; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Sequence (5’3’) Acc.Nr. 
Biglycan (+)-GAATGAACTCCACCTAGACCACAAC NM_001711 
 (–)-AGGCCCAGCCTGTACAGCTT  
CXCR5 (+)-GCCGGCACAGCCATGA NM_001716 
 (–)-CTGTCCAGTTCCCAGAACAGGT  
Fibromodulin (+)-CTCTCCCAGGCCCAGTATGA NM_002023 
 (–)-TAAGGGTCATAGGGATCGTAGTAGGT  
GAPDH (+)-CCAAGGTCATCCATGACAACTT NM_002046 
 (–)-AGGGGCCATCCACAGTCTT  
Lumican (+)-GGGCAATCATCACCAAACTGT NM_002345 
 (–)-AGGAGGCACCATTGGTACACTT  

III

IV

